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Extracellular vesicles (EVs) are small membrane bound vesicles that bud from the plasma and 
endosomal membranes of nearly all cell types. EVs do not have a defined morphology but have 
the same topology as the cells they bud from. They have gained prominence over the years because 
of their involvement in intercellular communication; cells can transmit signals, nuclei acids, 
proteins, carbohydrates and lipids to other cells in a non-viral pathway via extracellular vesicles. 
EVs have been implicated in numerous physiological processes such as protein quality control, 
differentiation, and cell polarity. They have also been shown to play important roles in pathological 
processes (e.g. cancer, viral infections and neurodegenerative disorders). 
 
The size and composition of extracellular vesicles vary significantly, and this has led to a 
proliferation of names for EVs, including exosomes, microvesicles, oncosomes, ectosomes, 
membrane particles, etc. Of these, the two most commonly used terms are exosomes and 
microvesicles. Some have proposed that exosomes be defined as vesicles that are released when 
multivesicular bodies (MVB) fuse with the plasma membrane, while microvesicles be defined as 
vesicles that bud directly from the plasma membrane. However, there is little empirical support 
for these distinctions, and the extent to which differences in EV size and composition are caused 
by stochastic variations or mechanistic differences is not yet known.  
 
Our understanding of organelle biogenesis has been shaped by detailed studies of individual cargo 
proteins. My thesis work advanced our mechanistic understanding of EV biogenesis using the 
same type of cargo-based approach. Specifically, in chapter 1, I tested the endosomal hypothesis 
of the current model of exosome biogenesis in HEK293 cells using the classical exosomal cargoes 
 iii 
(CD63, CD81 and CD9). I observed that (i) majority of these proteins are localized on the plasma 
membrane, (ii) cargo proteins localized on the plasma membrane bud better than those in the 
endosomes, and lastly (iii) redirecting cargo proteins from the endosome to the plasma membrane 
enhances their budding significantly. The most parsimonious explanation for these observations is 
that the majority of protein budding occurs at the plasma membrane of HEK293 and NIH3T3 cells, 
two of the most commonly used cell lines in biomedical research. 
 
In Chapter 2, I characterized the role of certain trans-acting factors that are required for the 
budding of classical exosomal markers. I showed that loss of tetraspanins, or other putative 
exosome factors such as alix and syntenin, do not cause a defect in the vesicular secretion of 
exosomal markers in HEK293 and 293T. Despite no defect in budding, I however noticed variation 
in the budding of exosome cargo proteins in some mutant clones. To identify the basis of this 
clonal heterogeneity in exosome biogenesis, I generated dozens of single cell clones (SCCs) from 
the parental HEK293 cell line and found that they varied by as much as 10-fold in their production 
of exosomes, demonstrating that the variation we observed in mutant cell lines was not due to the 
nature of the mutations we introduced or the other Cas9-induced mutations in our SCC lines. We 
next tested whether clonal heterogeneity in exosome biogenesis was a unique feature of HEK293 
cells by generating multiple SCCs from several other human cell lines, again in the absence of any 
mutagenesis. These experiments revealed that SCCs derived 293T, K562, and Hap1 cells also 
displayed pronounced clonal heterogeneity.  Furthermore, in collaboration with Louise Laurent, 
we found that SCCs derived from the human stem cell line WA09 also displayed pronounced 
clonal heterogeneity. We conclude from these results that the extent of exosome biogenesis in 
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human cultured cells is under a complex regulatory pathway that can switch from low to high 
activity and back as cells are subjected to single cell cloning. 
 
Lastly, I described my observations in the differences in exosome composition and production in 
HEK293 and HEK293T cells. I report an increase in budding of CD63, CD81 and CD9 in 
HEK293T compared to HEK293, and propose that the increase in budding is a result of the 
elevated nSMase2 levels observed in HEK293T. The mechanisms for how nSMase2 affects 
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Extracellular vesicles are small membrane bound organelles that are released from the 
plasma and endosomal membrane of eukaryotic cells. These vesicles were initially referred to as 
‘platelet dust’ by Wolf in 1967 when he showed that plasma devoid of platelet still had small 
particulate platelet material that were bound in phospholipid-rich membranes and could be 
separated from the plasma by ultracentrifugation1. During that same time, Bonucci2 and Anderson3 
described small roundish osmiophilic vesicles which were formed in the pericellular spaces prior 
to cartilage calcification. These vesicles contain crystallites and come together around collagenous 
fibrils and the cartilage matrix to initiate calcification. In 1980, Trams4 proposed the term 
‘exosome’ to describe ecto-enzyme containing vesicles from cultured cell lines that may have 
physiologic functions. The ‘exosomes’ isolated were enriched with phospholipids such as 
sphingomyelin and unsaturated fatty acids, so were concluded to probably bud from specific 
domains of the plasma membrane.  
However, in the late 1980’s, the term exosome was used to describe small membrane 
vesicles released by reticulocytes during differentiation5. Initial studies on reticulocyte maturation 
revealed that the transferrin receptor (TfR) could be detected in the intraluminal bodies of 
endosomes during its elimination from the plasma membrane, as well as its release on secreted 
vesicles6. These EM-based studies showed that TfR budding was a multi-step process involving 
its trafficking to the limiting membrane of the endosome, budding at that membrane to form 





Extracellular vesicles (EVs) have the same topology as the cell. The sizes can vary 
significantly, and this has led to a plethora of names in the field. Vesicles ranging from 30nm to 
200nm in diameter are referred to as exosomes, while larger vesicles with diameters more than 
200nm but less than 1000nm are classified as microvesicles. Oncosomes,8,9 on the other hand are 
large vesicles that bud from cancer cells and can be up to 10um in size. However, the extent to 
which these variations in size are caused by stochastic or mechanistic effect is not fully known, 
even though it has been proposed that large vesicles such as microvesicles and oncosomes bud 
from the plasma membrane and exosomes strictly bud from the endosome, these hypotheses have 
not been fully tested. Furthermore, experimental techniques used in assaying the sizes of 
extracellular vesicles may indirectly alter vesicle sizes as some of these experiments entails fixing 
with formaldehyde, freezing under high pressure, and treating with heavy metal salts. 
In addition to the size differences, there are variations in the shapes and structures of EVs. 
Exosomes isolated from HMC-1 cells were classified into nine different categories based on their 
shapes and structures when imaged using negative staining and cryo-EM10. The HMC-1 exosomes 
comprised of single vesicles which formed the majority, while double vesicles which contained a 
smaller vesicle enclosed in a larger vesicle, and triple vesicles where two vesicles were inside a 
larger one formed about 20%. They observed variations in the shape of the exosomes, while some 
had defined shapes such as round, oval, tubular, filamentous, they noticed some vesicles were 
pleomorphic. The heterogeneity in exosome morphologies could suggest that exosomes are made 
up of subpopulations which can have different functions and biochemistry. It is, however, 
important to note that there are currently no known mechanisms to explain the variations in shapes 
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and structures of exosomes, and there exist no protocols to isolate the different exosomal 
subpopulations. 
The density of exosomes ranges between 1.11 and 1.19 g/ml as a result of the variations in 
protein-lipid content of exosomes11. For example, exosomes secreted from mouse tumor breast 
cell line where Rab27a is inhibited has been shown to be less dense (1.11g/ml) compared to 
exosomes released from the wild type cell lines12. Fang et al showed that expression of a single 
protein such as AcylTyA in human T-cells can considerably alter the density of exosomes, and 
even affect their sizes and shapes13. In conclusion, size, shape and density cannot be used as 
determinants of exosomes since these characteristics vary significant depending on the 
protein:lipid compositions, cell line that they are budding from, physiologic state of the cell and 
how the vesicles are assayed. 
 
Exosome Composition 
Exosomes are enriched with a wide repertoire of proteins, lipids, nuclei acids and 
carbohydrates. These exosomal components can vary significantly from one cell to another, and 
even within a single cell. The variations can further be enhanced depending on the physiologic 
state of the cell. For instance, we have observed that HEK293T has significantly higher relative 
abundance of tetraspanins in exosomes than HEK293 even though both cell lines are embryonic 
kidney cells with the major difference being that HEK293T is transformed with SV40 large T 
antigen. Exosome composition can also change depending on the cell’s pathological state, as 
exosomes derived from diseased cells have significantly different composition compared to that 
of healthy cells14. Ling et al found that miR-195 is downregulated in LX2, human stellate cells 
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when co-cultured with human cholangiocarcinoma15. Extensive work done on the compositions of 
exosomes can be found in these databases: EVpedia16, Exocarta17, and Vesiclepedia18. 
 
Exosome Lipids 
 Lipidomic analyses have shown exosomes to be highly enriched in membrane lipids. These 
include phospholipids (phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI), sphingomyelin), cholesterol, ceramides, and 
glycolipids (glycosphingolipids)19-22. The relative abundance of these lipids is however different 
from the whole cell membrane. Exosome membranes have high amount of PE and PS on the outer 
membrane, while whole cell membrane have them in their inner membrane due to the activity of 
phospholipid flippases23,24. Another difference in lipid distribution is that of exosomes and MVB 
which they are presumed to bud. Exosomes have been shown to have high amount of cholesterol 
and very low lysobisphosphatidic acid (LBPA), which is in sharp contrast to the lipid composition 
of the limiting membrane MVB25. It is possible that MVB might not be a major site of budding or 
the lipid composition of MVB changes as it matures and progresses to the plasma membrane to 
release the vesicles. 
 Lipids play roles in exosome biogenesis by enhancing secretion of exosomes. Increasing 
ceramide levels by overexpressing nSMase2 in oligodendroglial cells26, HEK29327, and T-cells28 
resulted in an increased in exosome budding. The mechanism by which ceramide enhances 
exosomal secretion is unknown but it has been proposed that ceramide induces inward curvature 
of the limiting membranes of the sites of budding. Pharmacologic or genetically induced 
accumulation of cholesterol in MVB of Oli-neu cells has been shown to enhance secretion of 
exosomes carrying specific cargoes such as ALIX and Flotillin-229. It is important to note that the 
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mechanisms by which these lipids enhance exosome secretion is unknown even though it has been 
suggested that the lipids can induce membrane curvature or act as signal to stimulate a signaling 
pathway that enhances exosome biogenesis. 
 
Exosome Carbohydrates 
Complex polysaccharides are found on the surface of exosomes, attached to glycoproteins 
and lipids on the outer membranes. Glycomic analysis using lectin binding microarray has shown 
exosomes to be enriched with high mannose, polylactosamine, α-2,6 sialic acid, and complex N-
linked glycans30,31. These enrichments however vary across exosomes secreted from different cell 
lines as some cancer cells exosomes are enriched for polymers of hyaluronic acid32 and heparin 
sulfate glycans33.  
The presence or lack of these carbohydrates on the surface on exosomes can affect their 
uptake by recipient cells as they can change the physico-chemical properties of the membrane. 
Escrevente et al, showed that removal of N-acetylneuraminic acid (NeuAc) from the SKOV3 
cancer cell exosomes led to an increase in their uptake by the same cell34. NeuAc, which is a 
negatively charged carbohydrate, when removed likely resulted in a change of membrane charge 
which enhanced their uptake. The absence of NeuAc could also expose new carbohydrate residues 
which might have been the preferred ligands for carbohydrate binding proteins on the surface of 





Exosome Nuclei Acids 
Exosomes contain RNA and DNA, but these are not carried in large amount compared to 
other macromolecules. Despite the low abundance of these nuclei acids, sensitive methods of 
detection such as RNA-sequencing and reverse transcription and quantitative PCR analysis has 
shown exosomes to have single-stranded DNA, double-stranded DNA, genomic DNA, 
mitochondria DNA, coding RNAs (mRNA), and non-coding RNAs (miRNA, lncRNAs, 
circRNAs, snoRNAs, snRNAs, tRNAs, rRNAs)35-42. These nuclei acids expressed in exosomes 
are protected from nucleases and can be transferred to recipient cells or other parts of the same cell 
to be further expressed or to regulate expressions of other genes. Purified exosomes derived from 
Glioblastoma cancer cells expressing Gaussia luciferase (Gluc) mRNA increased the Gluc activity 
of human brain microvascular endothelial cells (HBMVECs) over 24 hours when co-cultured43,44.  
The process by which nuclei acids are incorporated into exosomes is not fully understood. 
DNA isolated and sequenced from pancreatic cancer cell derived exosomes reconstructed the 
entire genome of the producing cell without any bias for particular sequences. RNA on the other 
has been proposed to bud into exosomes by binding to other exosomal cargoes. For instance, Gag 
and Gag-like proteins binds their mRNA and co-import them into exosomes44,45. Ago-2 which is 
a protein involved in microRNA processing has been shown to bud into exosomes with other 
miRNAs46,47. Other proteins such as YBX136,48, SYNCRIP49, Hu50,51, and hnRNPA2B152 bind to 






Exosomes are highly enriched in selected proteins. These include integral membrane 
proteins, peripheral membrane proteins, lipid-anchored proteins and soluble proteins. It is 
important to note that just like the other macromolecules described earlier, the protein composition 
of exosomes varies significantly within clones of a single cell, and from one cell line to another.  
Escola et al53 were the first to show the presence of tetraspanins (4-transmembrane 
proteins) such as CD37, CD53, CD63, CD81, CD82, and CD86. Of these tetraspanins, CD81 was 
the most abundant and was enriched by 124-fold in exosomes while CD63 was the least enriched 
in exosomes by 7-fold. Other tetraspanins such as CD9, CD37, CD151, TSPAN7, TSPAN8, 
TSPAN16, etc. have been found in exosomes54. Tetraspanins act as molecular facilitators that 
interact with integrins and other transmembrane proteins to facilitate their trafficking in the cells55. 
These tetraspanins partners such as integrins56, MHC Class II proteins11, ICAM-157, syndecans58 
have been found in exosomes. It is likely that as tetraspanins are recruited into exosomes, their 
binding partners are automatically recruited too. Exosomes have been shown to also contain signal 
proteins, many of which tetraspanins interact with and facilitate their recruitments. Epidermal 
growth factor receptor (EGFR)59, T-cell receptor60, notch receptors61,62, G-protein couple 
receptors63,64, cytokine receptors63 and vascular endothelial growth factor (VEGF) receptor type 
265 are a few signal receptor molecules that have been identified in exosomes. Other signaling 
proteins such as tumor necrosis factor (TNF)66, TRAIL67, FAS ligand68 and TGFß69 have been 
found to be reside at the peripheral surface of exosomes. These signaling molecules can elicit 
functional signaling responses by binding to and activating receptors on recipient cells. 
Exosomes are enriched with membrane proteins which are anchored by lipids to the inner 
and outer membranes. C-terminal glycosylphosphotidylinositol (GPI) anchor proteins such as 
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ectonucleotidases CD39 and CD7370, decay accelerating factor CD55 and reactive lysis membrane 
inhibitor CD5971, glypian-172, Juno73 and prion proteins have been found in the outer leaflet of 
exosome membranes74. Proteins like Hedgehog (Hh), a secreted morphogen that is responsible for 
differentiation and patterning in developing animal tissues, has been shown to be linked to the 
outer membrane leaflet of exosomes by their cholesterol moiety75. The inner membrane leaflet is 
enriched with acylated proteins such as prenylated small GTPases like Rabs76,77, palmitoylated 
proteins present in the inner membrane of tumor derived exosomes78, and myristoylated signaling 
kinases like Src79,80. Scaffolding proteins have been found at the peripheral surface of the inner 
membrane lipids to crosslink the cytoplasmic tails of membrane proteins to one another and to 
other cargoes in the exosomes. These scaffolding proteins include Ezrin-Radixin-Moesin (ERM) 
a family protein which links membrane proteins to actin-based cytoskeleton81,82. Syntenin which 
has been found in exosomes secreted from MCF-7 cells and other cell lines binds to ALIX (ALG-
2-interacting protein X) via its three LYPXnL motifs on the N-terminus and to syndecans via the 
PDZ domains58,83. ALIX is also a scaffold protein that is enriched in exosomes, it interacts with 
CHMP4a/b and TSG101 which are components of ESCRT-I and ESCRT-III respectively84. The 
endosomal sorting complex required for transport (ESCRT) machinery consists of ESCRT-0, 
ESCRT-I, ESCRT-II and ESCRT-III protein complexes and these have been shown to be involved 
in a number of membrane remodeling events such as retroviral budding, cytokinetic abscission, 
MVB biogenesis, nuclear membrane reformation and autophagy85,86. It has been thought to be 
involved in exosome budding because of its enrichment in exosomes87, however silencing or 
deletion of ESCRT genes has not shown any significant defect in the budding of exosomes88,89. 
In addition to the membrane proteins, exosomes are enriched with soluble/cytosolic 
proteins such as chaperones90-93, cytoskeleton94-96, and enzymes90,97-99. These proteins are 
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surprisingly abundant in exosomes, however there is currently no evidence that they are involved 
in exosomes biogenesis or are selectively enriched in exosomes. It is therefore likely that they end 
up in exosomes non-selectively during cargo recruitment into exosomes. Chaperone proteins on 
the other hand bind to aggregated or misfolded proteins100 so can be recruited into exosomes when 
these proteins buds into exosomes. For instance, HSP70 interacts with TfR during maturation of 
the red blood cells, and both are secreted together into exosomes91. 
 
Exosome Biogenesis 
Sites of Exosome Budding 
The current dogma of exosome biogenesis predicts that exosomes bud from endosomes. 
Proteins are targeted to the endosomal limiting membrane where they bud. The endosome becomes 
laden with vesicles and then moves to the plasma membrane to fuse with it and release the 
exosomes. The vesicle laden endosomes are referred to as multivesicular bodies (MVB). This 
model is based on electron microscopic data which showed the vesicular externalization of the 
transferrin receptor in sheep reticulocytes6,7,101. Subsequently other studies have confirmed that 
exosomes can bud from the endosomes102. Knocking down Rab2777 or RAL-1103 showed 
accumulation of MVBs in cells and reduction in exosome level. In addition, using RNAi to 
inactivate HRS inhibits the formation and secretion of exosomes in dendritic cells89. HRS is an 
ESCRT-0 protein which functions with ESCRT-1 to cluster ubiquitylated cargoes onto the limiting 
membrane of endosomes before they bud. Experiments involving pH-sensitive GFP-pHLuorin 
moiety inserted into the first extracellular loop of CD63 has been used to show the fusion of MVEs 
with cell surface104. Deleting target membrane SNARES such as SNAP23 and syntaxin-4 
significantly inhibits the secretion of CD63-enriched exosomes in HeLa cells. Similarly, enhancing 
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activity of SNAP23 through the activation of H1R1 allows for rapid fusion of MVEs with plasma 
membrane105.  
While these experiments confirm exosomes can bud from the endosomes in some cells, 
other experiments indicate that exosomes also bud from the plasma membrane106-108. Exosomes 
from T-lymphocytes cells are secreted from the plasma membrane13,23,109; cargoes are targeted to 
discrete domains on the plasma membrane instead of the endosomes where they bud into the 
extracellular space13,23,110-112. Electron microscopy experiment has shown Glioblastoma cells 
(GBM20/3) shed most of their exosomes directly from the plasma membrane113. Juno protein 
which is the sperm surface receptor on egg also buds into exosomes from the egg surface 
immediately after fertilization73. Arrestin domain-containing protein (ARRDC) and G protein-
coupled receptors (GPCRs) bud from the plasma membrane. GPCRs cluster onto the plasma 
membranes of cilia where they bud directly into the extracellular milieu64. ARRDC on the other 
hand interacts with TSG101 and relocalizes it from the endosome to the plasma membrane where 
they bud together into exosomes114. 
 Fang et al.13 showed in Jurkat T cells that inducing higher-order oligomerization of plasma 
membrane proteins, and attaching high-order oligomeric cytoplasmic proteins to the plasma 
membrane via a short N-terminal acylation tag were sufficient to target them to the exosomes. 
These lines of evidence provide support for the hypothesis that the plasma membrane is a site for 
exosome budding. Shen et al.112 confirmed the budding of high-order cytosolic proteins from 
plasma membrane into exosomes using a variety of plasma membrane anchors such as (i) a 
myristoylation tag; (ii) a phosphatidylinositol-(4,5)-bisphosphate (PIP(2))-binding domain; (iii), a 
phosphatidylinositol-(3,4,5)-trisphosphate-binding domain; (iv) a prenylation/palmitoylation tag, 
and (v) a type-1 plasma membrane protein, CD43. It is important to note that targeting such cargoes 
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to the endosomal membrane budded rather poorly even though endosome membrane is the widely 
hypothesized site of exosome budding.  
 
Machineries Involved in Exosomes Biogenesis 
Exosomes biogenesis involves the targeting of cargoes to sites of budding (endosomes and 
plasma membranes), the budding of cargoes into small membrane bound vesicles, and their release 
into the extracellular space. A number of molecular machineries have been implicated in these 
processes.  
Lipids play an important role in exosome biogenesis. In order for exosomes to bud, 
membrane curvature must be induced, and this is made possible by lipids such as PE and PS that 
are able to form cone-shapes and inverted-cone shapes. Exosome outer membranes have relatively 
high levels of PE and PS, and this is in sharp contrast to the outer leaflet of plasma membrane 
which has relatively low levels of PE and PS. The low abundance of these lipids is due to the 
activity of phospholipid flippases, which transport PE and PS from the outer leaflet to the inner 
leaflet. However, there are discrete domains of the plasma membrane that are enriched with PE on 
the outer leaflet, these domains serve as site for exosome budding13,23. Wehmann et al.115 showed 
that deleting TAT-5 phospholipid flippase in C. elegans results in an increase in exosome 
secretion. They suggested that loss of TAT-5 exposes PE on the outer leaflet thereby inducing a 
membrane curvature that favors exosome secretion.  
Exosomes secreted from MCF-7 and RBL-2H3 cells contain Phospholipase D2 (PLD2), 
an enzyme that catalyzes the hydrolysis of phosphocholine (PC) to choline and phosphatidic acid 
(PA), a cone shaped lipid. Laulagnier et al.116 showed that increasing PLD2 levels in RBL-2H3 
cells with an expression vector or by stimulating with ionomycin enhanced exosomes secretion. 
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The model suggested is that an increase in PLD2 will result in an increase in PA levels in the inner 
leaflet of MVB’s limiting membrane which would induce membrane curvature and thus formation 
of vesicles117,118. Ceramide is another important lipid that has been implicated in exosome 
biogenesis. It has been shown that exosomes secretion is significantly impaired when neutral 
sphingomyelinase 2 (nSMase2) is inhibited with GW486926. nSMase2 catalyzes the production of 
ceramide from the hydrolysis of sphingomyelin119. It has been proposed that ceramide induces 
membrane curvature that favors excision of vesicles from the cells. It is important to note that 
ceramide is also a second messenger so can activate a number of pathways which can in turn 
stimulate exosome production. 
 
Endosomal Sorting Complexes Required for Transport (ESCRT) 
 ESCRT were identified in yeast as protein complexes involved in the sorting of cargoes 
into vesicles during the formation of MVB (multivesicular bodies)85,120. They have subsequently 
been found to be involved in envelope viral budding, cytokinesis, wound repair, neuron pruning, 
defective nuclear pore extraction, nuclear envelope reformation and autophagy121. ESCRT consists 
of five different protein complexes denoted as ESCRTs -0, -I, -II, -III, and AAA ATPase Vps4 
complex. ESCRT-0 binds and sequesters ubiquitinated cargoes on the surface of the cell, ESCRT-
I together with ESCRT-II are responsible for budding of membrane and protein, ESCRT-III drives 
vesicle scission, and AAA ATPase Vps4 is responsible for the disassembling and recycling of the 
ESCRT machinery122.  
 The mechanisms for exosome biogenesis have been hypothesized to be dependent on 
ESCRT due to the similarities between the exosome biogenesis processes and other processes in 
which ESCRT machinery have been implicated. However, a number of independent studies have 
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shown a minimal reduction in exosome secretion when ESCRT-0 and -I components are depleted, 
and no effect on the budding of exosomes when the ESCRT function is blocked by inhibition of 
VPS4. For instance, inhibiting HRS, an ESCRT-0 protein in HeLa cells88, HEK293123, mouse 
dendritic cell89, and head and neck squamous cell carcinoma124 resulted in a defect in exosome 
secretion, but an RNA interference screen targeting ESCRT -II and -III proteins in HeLa cells 
showed no defect in exosome secretion88. It is possible that these effects might be cell line specific 
as depletion of CHMP4, an ESCRT-III protein showed some reduction in exosome secretion of 
MCF-7 cell line58. Also, inhibiting TSG101, an ESCRT-I protein resulted in a defect in exosome 
budding of HeLa88, MCF-758 and RPE1125 cells, but not in oligodendroglial cells26. 
 AAA ATPase VPS4, the complex responsible for disassembling and recycling the ESCRT 
components has been shown in vivo to block all ESCRT-dependent processes when its catalytic 
activity is silenced. However, expressing a dominant negative VPS4 in human cells does not 
significantly affect budding of exosomal tetraspanins, even though it completely inhibits HIV 
budding and cytokinesis13,88. Trajkovic confirmed this observation in oli-neu cells26. It is important 
to note that VPS4 has two isoforms and inhibiting both isoforms has no significant effect on 
exosome secretion but inhibiting one of the isoforms (VPS4B) in HeLa cells has been shown to 
result in an increase in exosome secretion88.  
 In conclusion, the mechanisms for exosome biogenesis cannot be said to be dependent on 
ESCRT since inactivation of VPS4 does not significantly affect exosome production. The 
mechanisms also vary among cell lines since while depleting or inhibiting a protein might have an 
effect on the biogenesis in one cell line, its inhibition might have the opposite or no effect at all in 




Rab GTPases are a large family of small GTPases that regulate membrane identity and 
control the steps involved in intracellular vesicle trafficking such as vesicle budding, vesicle 
transport along cytoskeletal elements, and membrane fusion126. Rab proteins have been identified 
in exosomes and implicated in exosome biogenesis but the precise mechanism of their involvement 
is not fully understood. Rab11 was the first Rab GTPase identified to affect exosome secretion. 
Savina et al showed that vesicular secretion of transferrin receptor, Lyn and chaperone protein 
HSC70 are impaired in K562 cells when overexpressed with a dominant negative Rab11 mutant127. 
Similarly, inhibiting Rab11 in Drosophila S2 cells reduced the budding of Evi-containing 
exosomes128. 
Subsequently, several other Rabs have been found to affect exosome secretion through 
genetic screens. Rab35, when inhibited in oli-neu cells impaired the budding of proteolipid 
proteins (PLP) in exosomes76. Fruhbeis et al. also noted a reduction in exosome secretion when 
Rab35 was silenced in oli-neu cells129. Ostrowski et al.77 using RNA interference (RNAi) screen 
identified five different Rab GTPases that affect exosome secretion in HeLa cells. They found that 
depletion of Rab2b, Rab5a, Rab9a, Rab27a and Rab27b in HeLa cells resulted in a decrease in 
secretion of exosomes which was assayed using flow cytometry to detect anti-CD81 and anti-MHC 
exosomes bound on anti-CD63 beads. They observed using TIRF microscopy that silencing 
Rab27a resulted in an increase in the sizes of the MVE, while MVEs were redirected towards the 
perinuclear area when Rab27b is depleted. This same phenotype was observed when Slp4 and 
Slac2b which are effectors of Rab27. It was therefore proposed that Rab27 is an important of 
exosome biogenesis and it regulates the maturation of MVEs and their docking to the plasma 
membrane to release exosomes. It important to note that even though several studies have shown 
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the effects of Rab27 on exosome biogenesis in different cell lines124,130-132, however some studies 
have shown no significant defect on exosome biogenesis when Rab27 is depleted125,128. Similarly, 
Rab7 has been shown by Baietti et al.58 to affect the budding of syntenin, ALIX and syndecans in 
exosomes of MCF-7 cells but no effect was observed in exosome secretion in HeLa cells. 
 
Syndecan-Syntenin-ALIX Pathway 
Baietti et al.58 observed that depleting syndecan, syntenin, and ALIX in MCF-7 cells 
significantly impair exosome secretion. They also established using electron microscopy, that 
knocking down syntenin affects the formation of intraluminal vesicles in the endosomes and 
proposed that syndecan interacts with syntenin which connects to ALIX, an accessory component 
of the ESCRT machinery that supports endosomal membrane budding and scission. Additional 
experiments have shown that the silencing of ALIX in dendritic88 and muscle cells133 result in a 
reduction of the budding of CD63 positive exosomes.  
 
ARF6-PLD2 Pathway 
ADP ribosylation factor 6 (ARF6) and its effector phospholipase D2 (PLD2) have been 
implicated in the exosome biogenesis pathway. Ghossoub et al.117 showed that budding of 
syntenin, ALIX and CD63 is significantly reduced when MCF-7 cells are treated with a PLD-2 
inhibitor, thereby implicating PLD-2 in exosome biogenesis. They also confirmed the effect of 
PLD-2 using confocal microscopy to assess enrichment of exogenous syntenin in the endosomal 
lumen of a PLD-2 depleted cell. They observed that syntenin is significantly reduced in the lumen 
when PLD-2 is silenced, and so suggested that PLD2 is involved in the packaging of syntenin in 
endosomal lumen before they bud into exosomes. Depleting of ARF6 significantly impairs the 
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vesicular secretion of syntenin, ALIX and CD63. In contrast, overexpressing ARF6 in MCF-7 
enhances the budding of these cargoes. To investigate the role of ARF6 in exosome biogenesis, 
the authors performed electron microscopy to assess the ultrastructure of the endosomes of ARF6 
depleted cells, and observed the lumen of the endosomes to be virtually empty with minimal ILVs 
at the periphery. They therefore proposed that ARF6 is involved in formation of the ILV. 
It is important to note that ARF6 and PLD2 have also been implicated in the budding of 
exosomes from the plasma membrane in tumor cells. Vandhana et al.134 observed a significant 
decrease in exosomes collected from multiple tumor cell lines expressing a mutant ARF6 where 
the GTPase activity is inhibited. Using microscopy, they observed an accumulation of more 
exosome structures within the cell and these were localized around the plasma membrane. They 
proposed that ARF6 activity stimulates PLD2 which in turn activates the ERK pathway, thus 
allowing the actomyosin-based budding of the exosomes into the extracellular space. 
 
Biological Significance of Exosomes 
 Exosomes have been implicated in a number of physiological processes such as cellular 
homeostasis135, calcification of extracellular matrix2,3, cell polarity111, migration111, germ cell 
development136 and cell-to-cell communication.  
Exosomes may participate in intra-cellular homeostasis by selectively budding out toxic 
and obsolete macromolecules from the cell. Johnstone et al.7 reported this role of exosomes when 
they described the mechanisms by which reticulocytes get rid of transferrin receptor during 
maturation into erythrocytes. They observed TfR was trafficked from the plasma membrane into 
small vesicles in the endosomes which were later secreted out of the cell. Cells can get rid of 
misfolded and aggregated proteins such Prions, Tau, α-synuclein and amyloid β by secreting via 
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exosomes137,138. Juno, the sperm receptor on the egg surface buds off into exosomes immediately 
after a sperm fuses with the egg in order to prevent polyspermy73. 
In addition to cellular homeostasis, exosomes play a role in establishing cell polarity. In 
leukocytes, exosomal biogenesis pathway generates a polarized protein sorting pathway where 
higher-order oligomerized proteins and proteins attached to the plasma membrane are trafficked 
to the posterior pole of cells. This overlap between exosomal proteins and the posterior pole of 
cells can generate anterior-posterior morphology in non-polarized cells, which is critical for 
directed cell migration111. 
Exosomes have been found to participate in cellular communications through their 
transmission of signals and molecules. Exosomes containing miRNA have been shown to reduce 
target mRNA expression levels in the recipient cells. Mittebrunn et al.28 tested the functionality of 
T cell exosomes containing miR-335 in antigen-presenting cells (APC) using a SOX4 luciferase 
reporter assay. They found the internalization of miR-335 containing exosomes by APC led to a 
decrease in SOX4 luciferase activity. Exosomes secreted from dendritic cells have also been 
shown to enhance immunogenicity and differentiation of T helper cells. Choudhuri et al.139 
observed that T cells release exosomes containing T cell receptors (TCR) at the immunological 
synapses which engage with peptide-bound MHC molecules on B cells to initiate T cell signaling. 
These experiments underscore the involvement of exosomes in cellular communication. 
Exosomes have been shown to be involved in many pathophysiological processes. They 
have been implicated in multiple human diseases such as HIV, Herpes, Hepatitis, cancer and 
neurodegenerative disorders. It has been postulated that HIV and other retroviruses exploit the 
exosome biogenesis pathway for the budding of their viral particles140. This hypothesis is based 
on the similarities in (i) lipids and proteins compositions of exosomes and retroviruses; (ii) protein 
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targeting and vesicle biogenesis; and (iii) the release of exosomes and viral particles from the cell. 
Fang et al. demonstrated that proteins bud into both exosomes and virus particles when targeted to 
discrete domains on the plasma membrane. They also showed that HIV Gag proteins possess 
exosomal sorting information, and that higher-order oligomerization is the principal factor for their 
budding into exosomes and viral particles13. 
Neurodegenerative disorders are characterized by the progressive loss of neurons and are 
linked with the accumulation of misfolded proteins and infectious isoforms. The aggregation of 
these proteins can target them to site of budding where they are secreted into exosomes. In prion 
diseases, both normal (PrPC) and infectious isoforms (PrPSc)of prion protein have been found in 
exosomes isolated from neuronal cells and blood74,141. Fevrier et al.138 showed PrPSc can catalyze 
the infection of normal PrPC when they incubated Rov cells with isolated exosomes from prion 
infected Rov cells. They observed the presence of PrPSc in normal cells after a number of passages 
which indicated the transfer of infectivity. They further confirmed this, by inoculating transgenic 
mice that were highly susceptible to prions, with PrPSc containing exosomes, and observed that all 
the inoculated mice died as a result of acute neurological disorder. Other proteins and nuclei acids 
related to neurodegenerative disorders such α-synucleins142, tau143, β-amyloids144, and SOD1145 
have been found in exosomes and have demonstrated a prion-like infection. These findings suggest 
a role for exosomes in the transmission of diseases within a host cell and among organisms, even 
though the mechanisms are not fully understood.  
 
Objectives 
Exosomes have been shown to be of enormous biological importance in a number of 
physiological and pathological processes. However, the mechanisms by which exosomes are 
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made, and how cargoes are targeted to exosomes are not fully understood. The current dogma of 
exosome biogenesis is that cargoes are targeted to the limiting membrane of endosomes where 
they bud to form a vesicle laden endosome referred to as MVB, which then moves to fuse with the 
plasma membrane to release the vesicles, but this has not been rigorously tested. The objective of 
my thesis is to enhance our mechanistic understanding of exosome biogenesis by (i) identifying 
cis-acting signals on cargoes that target them to exosomes, and (ii) characterizing trans-acting 
factors that are required for budding of exosomes.  
Specifically, in chapter 1, I investigated the endosomal trafficking of the current dogma of 
exosome biogenesis in HEK293 cells using the classical exosomal markers. I found that most of 
these markers (CD81 and CD9) are abundant on the plasma membrane and bud significantly better 
than CD63 which is localized in the endosomes. I observed that redirecting CD9 which is primarily 
localized on the plasma membrane to the endosomes resulted in a decrease in budding while CD63 
budded significantly better when mislocalized to the plasma membrane. Using single-particle 
interferometry reflectance imaging and immunofluorescence microscopy, I showed that exosome 
composition can be determined by intracellular protein trafficking pathways, as misdirecting an 
exosomal cargo from the endosome to the plasma membrane results in an increase its its exosomal 
co-localization with plasma membrane-localized exosome cargoes. I also showed that the converse 
is true, that misdirecting a plasma membrane-enriched exosome cargo to endosomes results in a 
decrease in its exosomal co-localization with plasma membrane-localized exosome cargoes, and 
an increase in its exosomal co-localization with endosome-enriched exosome cargoes. I conclude 
that exosomes can bud from both the plasma and endosome membranes in HEK293 and NIH3T3 
cells, bud even better from the plasma than endosome membranes in these two cell lines, and that 
 21 
exosome engineering is best accomplished by targeting potentially new cargoes to the plasma 
rather than endosome membrane.  
Chapter 2, I identified and characterized proteins that have been implicated in the budding 
of exosomes. I knocked out tetraspanins and other putative exosome factors using CRISPR/Cas9 
technology in HEK293 and 293T cells and assessed the effects on relative budding of classical 
markers, synthetic cargoes and vesicle concentration. I observed that loss of CD63, CD81, CD9, 
Alix or Syntenin does not cause any significant defect in the budding of classical exosomal markers 
and exogenous cargoes. I also did not observe any significant effect in the budding of vesicles in 
HEK293 cells lacking CD63, CD81 or CD9. I however noticed significant clonal variations in the 
budding of markers as some clones of these mutants had enhanced budding even though none 
showed any defect. To explore this clonal variability, I single cell cloned wildtype HEK293 cells 
and found this same phenotype among the selected clones. I went on to single cell clone other cell 
lines and observed a similar phenotype where the relative budding of classical exosomal markers 
varied significantly from one clone to another in the same cell line. This indicates that the relative 
rate of exosome production can vary significantly among cells in the absence of mutagenesis and 
this can be inadvertently exposed during isolation of single cell clones.  
In Chapter 3, I report my observations in the exosomal protein compositions of HEK293 
and HEK293T, and suggest a mechanism for the significant differences in the budding of classical 
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Eukaryotic cells secrete exosomes, which are small (~30-200 nm dia.), single membrane-bound 
organelles that transmit signals and molecules to other cells. Exosome-mediated signaling 
contributes to diverse physiological and disease processes, rendering their biogenesis of high 
biomedical importance. The prevailing hypothesis is that exosomes bud exclusively at endosome 
membranes and are released only upon endosome fusion with the plasma membrane. Here we 
tested this hypothesis by examining the intracellular sorting and exosomal secretion of the 
exosome cargo proteins CD63, CD9, and CD81. We report here that CD9 and CD81 are both 
localized to the plasma membrane and bud >5-fold more efficiently than endosome-localized 
CD63. Furthermore, we show that redirecting CD63 from endosomes to the plasma membrane by 
mutating its endocytosis signal (CD63/Y235A) increased its exosomal secretion ~6-fold, whereas 
redirecting CD9 to endosomes by adding an endosome targeting signal (CD9/YEVM) reduced its 
exosomal secretion ~5-fold. These data demonstrate that the plasma membrane is a major site of 
exosome biogenesis, and more importantly, that cells possess a common pathway for exosome 
protein budding that operates at both plasma and endosome membranes. Using a combination of 
single-particle interferometry reflectance (SPIR) imaging and immunofluorescence (IF) 
microscopy, we also show that variations in exosome composition are controlled by differential 
intracellular protein trafficking rather than by separate mechanisms of exosome biogenesis. This 
new view of exosome biogenesis offers a simple explanation for the pronounced compositional 
heterogeneity of exosomes and a validated roadmap for exosome engineering.   
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Introduction 
Exosomes are secreted by virtually all eukaryotic cells. These small vesicles are ~30-200 nm dia., 
have the same topology as the cell, and are enriched in selected proteins, lipids, and nucleic 
acids(Pegtel and Gould, 2019). Exosomes contribute to numerous physiological processes, 
including development, immunity, neuronal signaling, etc.(Ashley et al., 2018; Lindenbergh and 
Stoorvogel, 2018; McGough and Vincent, 2016; Pastuzyn et al., 2018), as well as a wide array 
human diseases, such as cancer, neurodegeneration, infectious disease, etc.(Becker et al., 2016; 
Cheng et al., 2018; Gould et al., 2003; van Dongen et al., 2016). Moreover, exosomes are abundant 
in all biofluids, can be used for clinical liquid biopsies, and are being developed as intrinsic 
therapeutics as well as drug delivery vehicles(Jia et al., 2014; Li et al., 2017; Phinney and Pittenger, 
2017). This breadth of biological importance and translational potential highlights the importance 
of elucidating the mechanisms of exosome biogenesis. 
 
In their landmark description of secreted vesicles, Trams et al.(Trams et al., 1981) defined 
exosomes as secreted vesicles that ‘may serve a physiological purpose’ and showed that cells 
secrete two classes of extracellular vesicles (EVs), one that is small, ~40 nm dia., and  another that 
is considerably larger, >500 nm dia. This ~10-fold difference in size allows their separation by 
differential centrifugation, which led to the eventual restriction of the term exosome to mean the 
smaller class of secreted vesicles, and adoption of the term microvesicle to describe the large class 
of secreted vesicles(Gould and Raposo, 2013). More recently, there has been a concerted effort to 
redefine these terms yet again, this time on the basis of biogenic mechanism. However, this effort 
has instead led to redefinition based on the site where an exosome originated in the cell, rather 
than the actual mechanism of biogenesis, and the now-commonplace dogma that that exosomes 
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arise only by budding into the endosome lumen(Colombo et al., 2014; Crenshaw et al., 2018; 
Desrochers et al., 2016; Mathieu et al., 2019; van Niel et al., 2018). While there is abundant 
evidence that exosomes can arise in this manner, the prevailing, ‘endosome-only’ hypothesis of 
exosomes biogenesis is not supported by clear evidence that exosomes and exosome cargoes 
cannot bud from the plasma membrane. In fact, it is fair to say that the ‘endosome-only’ hypothesis 
has yet to be tested. 
 
Highly reductionist, cargo-based studies provided critical early insights into the biogenesis of the 
endoplasmic reticulum(Blobel and Dobberstein, 1975a; Blobel and Dobberstein, 1975b; Blobel 
and Sabatini, 1971), nucleus(Kalderon et al., 1984), mitochondria(Horwich et al., 1985), 
peroxisome(Gould et al., 1989) and other organelles(Blobel, 1980; Blobel, 1995). It is therefore 
reasonable to use a similar approach in studies of exosome biogenesis. This requires a focus on 
the most highly enriched exosomal proteins, as these show the strongest evidence of active sorting 
into exosomes, which are the  tetraspanins CD63, CD9, and CD81(Escola et al., 1998; Thery et 
al., 1999), a trio of proteins that are widely used as exosome markers(Colombo et al., 2014; 
Crenshaw et al., 2018; Desrochers et al., 2016; Mathieu et al., 2019; van Niel et al., 2018). Like 
all tetraspanins, these proteins are co-translationally translocated into the ER lumen and 
membrane, span the membrane 4 times, and have their N-terminus and C-terminus oriented into 
the cytoplasm. The remainder of this paper tests several predictions of the ‘endosome-only’ 
hypothesis of exosome biogenesis by following the intracellular sorting and exosomal secretion of 
these cargo proteins, particularly CD63 and CD9. Our data represent argue against the ‘endosome-
only’ model and instead indicate that cells make exosomes by a common mechanism that acts 
across the spectrum of plasma and endosome membranes.  
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Results 
A key tenet of the ‘endosome-only’ hypothesis of exosome biogenesis is that exosome cargo 
proteins must be targeted to the limiting membrane of endosomes as a prerequisite to their 
exosomal secretion. To assess the validity of this prediction, we first examined the subcellular 
distribution of three well-established exosome marker proteins, CD63, CD9, and CD81(Escola et 
al., 1998; Thery et al., 1999). Using immunofluorescence microscopy (IFM), we observed that 
CD9 and CD81 were highly enriched at the plasma membrane instead of at endosomes, and that 
only CD63 displayed an endosomal localization (Fig. 1A). Although these distributions do not 
argue against the ‘endosome-only’ hypothesis of exosome biogenesis, they can only be reconciled 
with this hypothesis if CD63 buds more efficiently into exosomes than either CD9 or CD81. 
However, when we measured the relative budding of these proteins, we observed the exact 
opposite result. Specifically, we observed that CD9 displayed a relative budding that was ~5-fold 
higher than CD63 (4.9 +/- 0.53 fold higher; Student’s t-test p-value (p) = 0.0053; n = 4) and that 
CD81 displayed a relative budding ~15-fold higher CD63 (15.7 +/- 2.9 fold higher; p = 0.015; n = 
4) (Fig. 1B). 
 
These observations are inconsistent with the ‘endosome-only’ model of exosome biogenesis and 
instead raise the possibility that exosome cargo proteins, and thus exosomes, also bud directly 
from plasma, and that in HEK293 cells they may bud more efficiently from the plasma membrane 
than from endosome membranes. To differentiate between these models of exosome biogenesis 
we redirected CD63 from endosomes to the plasma membrane by eliminating it consitiutive 
endocytosis signal. If the endosome-only hypothesis is correct, then this shift should cause a severe 
reduction in the exosomal secretion of CD63. However, if HEK293 cells bud exosomes from 
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plasma membranes, the budding of plasma membrane-localized CD63 should remain strong. To 
execute this experiment, we created plasmids designed to express either WT CD63 or 
CD63/Y235A, a mutant form of CD63 carrying a mutation that disrupts its clathrin-mediated 
endocytosis (YEVMCOOH, where the Y235 reside critical for binding to the clathrin AP-2 adaptor 
complex is underlined(Bonifacino and Traub, 2003)). These plasmids were then transfected into 
CD63-/- cells(Fordjour et al., 2016) and the resulting cells were subsequently processed by IFM to 
assess the subcellular distribution of WT CD63 and CD63/Y235A. As expected, WT CD63 was 
localized primarily in endosomes, whereas CD63/Y235A was localized primarily at the plasma 
membrane (Fig. 2A). Exosome and cell lysates were also collected from these cultures, and 
subsequent IB analysis to assess the relative budding of these proteins. Once again, the data were 
the exact opposite of that predicted by the endosome-only hypothesis of exosome biogenesis (Fig. 
2B). Specifically, the plasma membrane-localized CD63/Y235A protein displayed ~6-fold higher 
relative budding than endosome-localized, WT CD63 (6.1-fold; +/- 1.3-fold, p = 0.0038; n = 9).  
 
The most parsimonious interpretation of these data is that cells can make exosomes at both plasma 
and endosome membranes, and that the plasma membrane is the predominant site of exosome 
budding in HEK293 cells. If this interpretation is correct, then WT CD63-containing exosomes 
should be the same size as CD63/Y235A-containing exosomes. To test this prediction, we used 
single-particle interferometry reflectance (SPIR) imaging(Avci et al., 2015; Daaboul et al., 2017; 
Daaboul et al., 2016; Sevenler et al., 2017; Sevenler et al., 2018) and immunofluorescence 
microscopy (IFM) to measure the sizes of thousands of WT CD63 exosomes and CD63/Y235A 
exosomes. SPIRI-IFM is a novel analytical approach that combines traditional IFM of 
immunolabeled exosomes with label-free visualization of exosomes using a single-particle 
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interferometric reflectance imaging sensor, in which the interference of light reflected from the 
sensor surface is (i) modified by the presence of a chip-bound exosome, (ii) varies in relation to 
the diameter of the chip-bound exosome, and (iii) allows measurement of exosome diameter to a 
resolution of 0.5 nm. In these experiments, exosomes were collected from the conditioned media 
of CD63-/- cells expressing either WT CD63 or CD63/Y235A. These were then incubated with 
SPIRI chips that had been previously functionalized with anti-CD63 antibodies. The chips were 
washed, the chip surface was incubated with fluorescently labeled antibodies specific for CD63, 
washed again, and the bound exosomes analyzed by SPIRI-IFM to (a) measure the  sizes of 
thousands of individual exosomes and (b) confirm the exosomal nature of each exosome by the 
presence of anti-CD63 fluorescence. The resulting data revealed that WT CD63 exosomes and 
CD63/Y235A exosomes have size distribution profiles that are virtually identical (Fig. 2C), and 
average diameters that are nearly the same (69 nm for WT CD63 exosomes (n = 3686) and 65 nm 
for CD63/Y235A exosomes (n = 5569)).  
 
These findings show that cells will bud CD63 in exosomes of the same size, regardless of whether 
CD63 is localized at endosome membranes or localized at the plasma membrane. The result 
represents strong evidence that cells possess a common pathway for budding exosomes from both 
plasma and endosome membranes. If this interpretation is correct, then the composition of 
individual exosomes will be heavily influenced by the local concentration of exosome cargo 
molecules. To test this prediction, we asked if WT CD63 exosomes and CD63/Y235A exosomes 
differed in their inclusion of CD9, a plasma membrane-localized exosome cargo. Specifically, we 
incubated these two exosome populations on SPIRI chips functionalized with either anti-CD63 or 
anti-CD9 antibodies, and then probed them with fluorescently-tagged antibodies specific for both 
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CD63 and CD9. The resulting data support this new view of exosome biogenesis as they show 
pronounced increase in the exosomal co-localization of these proteins on CD63/Y235A-containing 
exosomes (Fig. 2D). For example, when exosomes were captured on anti-CD63 antibodies and 
interrogated for the presence of CD9, only 20% of WT CD63-containing exosomes stained 
positive for CD9 (20% +/- 1%) whereas >80% of CD63/Y235A exosomes stained positive for 
CD9 (86% +/- 21%), a 4.3-fold increase (p = 0.00011; n = 3). Similar results were observed when 
these exosomes were captured on anti-CD9 antibodies and stained for CD63, which revealed an 
exosomal co-localization of CD63 on a quarter (25% +/- 7%) of CD9-captured exosomes from 
WT CD63-expressing cells, and an exosomal co-localization of CD63 on >90% of CD9-captured 
exosomes from cells expressing CD63/Y235 (91% +/- 5%), a 3.6-fold increase (p = 0.032; n = 3).  
 
The pronounced increase in the exosomal co-localization of CD9 on CD63/Y235A exosomes vs 
WT CD63 exosomes can also be visualized by plotting fluorescence intensity for thousands of 
individual exosomes (Fig. 2E, F). This is evident from comparing plots of anti-CD9 fluorescence 
intensity for (left panel) WT CD63 exosomes captured on anti-CD63 antibodies to those of (right 
panel) CD63/Y235A exosomes captured on anti-CD63 antibodies (Fig. 2E). It can also be seen in 
plots of anti-CD63 fluorescence intensity for (left panel) WT CD63 exosomes captured on anti-
CD9 antibodies and (right panel) CD63/Y235A exosomes captured on anti-CD9 antibodies (Fig. 
2F).  
 
The simplest interpretation of the above data is that CD63 and CD9 bud by a common mechanism 
that operates across the spectrum of endosome and plasma membranes, and that the composition 
of any individual exosome is determined in large part by the local concentration of other exosome 
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cargoes. If this model is correct, then the same trends should be observed upon redirecting CD9 
from plasma to endosome membrane. Towards this end, we generated CD9-/- HEK293 cells 
(supplementary figure S1) and then transfected them with with plasmids designed to express either 
WT CD9 or CD9/YEVM, a form of CD9 that carries the constitutive endocytosis signal from 
CD63 (YEVMCOOH). Immunofluorescence microscopy of these cells confirmed that WT CD9 was 
correctly localized to the plasma membrane and that CD9/YEVM was redirected to endosome 
membranes (Fig. 3A). Furthermore, IB analysis of cell and exosome fractions prepared from these 
cell populations revealed that redirecting CD9 from the plasma membrane to endosomes resulted 
in an ~5-fold reduction in its relative budding compared to that of WT CD9 (Fig. 3B; 5.5-fold 
difference; p = 0.00019; n = 9), demonstrating once again that the plasma membrane-localized 
form of a protein buds better than its endosome-targeted counterpart. 
 
To further characterize WT CD9 exosomes and CD9/YEVM exosomes, we once again employed 
SPIRI-IFM.  WT CD9 exosomes and CD9/YEVM exosomes were incubated with to anti-CD9 
antibody-functionalized SPIRI chips, bound exosomes were then stained with anti-CD9 
antibodies, and the chips were interrogated by SPIRI-IFM. The resulting data revealed that WT 
CD9 exosomes and CD9/YEVM exosomes have similar size distribution profiles (Fig. 3C) and 
average diameters (67 nm for WT CD9 exosomes (n = 15,684)  and 65 nm for CD9/YEVM 
exosomes (n = 18,232)), demonstrating that these proteins bud from the cell in bona fide exosomes. 
 
The budding of both CD9 and CD9/YEVM in exosomes of the same size supports the idea that 
cells make exosomes from both plasma and endosome membranes. If this interpretation is correct, 
then the antigenic character of WT CD9 exosomes and CD9/YEVM exosomes should differ in 
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respect to CD81 and CD63, with WT CD9 exosomes showing a higher degree of exosomal co-
localization with plasma membrane-enriched CD81, and CD9/YEVM showing a higher degree of 
exosomal co-localization with endosome-localized CD63. To test this prediction, WT CD9 
exosomes and CD9/YEVM exosomes were bound to anti-CD9-functionalized SPIRI chips, 
incubated with antibodies specific for CD81 and CD63, and subjected to SPIRI-IFM (Fig. 3D). 
The resulting data revealed that the ratio of CD81-positive exosomes to CD63-positive exosomes 
was 2.8 (+/- 0.3) for WT CD9 exosomes, but fell 5.5-fold for CD9/YEVM exosomes to 0.51 (+/- 
0.06), a decrease of high significance (p = 0.000020; n = 9).  This shift in antigenic character is 
also reflected in a 4-fold decrease (p = 0.0037; n = 9) in the percentage of CD9-containing 
exosomes that contain CD81 (from 23% +/- 4% for WT CD9 exosomes to 5.4% +/- 0.7% for 
CD9/YEVM exosomes). It is also evident in a 1.7-fold increase (p = 0.011, n = 9) in the percentage 
of CD63-captured exosomes that contain CD9 (from 26% +/- 3% for WT CD9 exosomes to 41% 
+/- 2% for CD9/YEVM exosomes).  
 
These changes in the exosomal co-localization of CD81, CD63 and CD9 can also be visualized by 
scatter plots of fluorescence intensity for thousands of individual exosomes (Fig. 3E, F). This is 
particularly evident from plotting anti-CD81 fluorescence intensity (a.u.) for (left panel) WT CD9-
exosomes captured on anti-CD9 antibodies and (right panel) CD9/YEVM exosome captured on 
anti-CD9 antibodies (Fig. 3E). It can also be seen by plotting anti-CD9 fluorescence intensity 
(a.u.) for (left panel) WT CD9 exosomes captured on anti-CD63 antibodies and (right panel) 
CD9/YEVM exosomes captured on anti-CD63 antibodies (Fig. 3F). 
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Our model is agnostic on the point of whether cells bud exosomes predominantly from the plasma 
or endosome membranes, as we presume that both are possible. Nevertheless, the observation that 
HEK293 cells display such a pronounced preference for making exosomes from the plasma 
membrane raises the question of whether this is also true for any other cell types. To answer this 
question we expressed the WT CD63, CD63/Y235A, WT CD9, and CD9/YEVM proteins in 
mouse NIH3T3 fibroblasts and followed their intracellular sorting and exosomal secretion (Fig. 
4). More specifically, we transfected NIH3T3 cells with plasmids designed to express each protein, 
selected for G418-resistant clones, and assayed each for levels of expression to obtain matched 
pairs of cell lines that express similar levels of each cargo protein. Each cell line was then subjected 
to IFM to determine the subcellular distribution of the protein of interest, and immunoblot analysis 
was used assess their relative budding. As expected, CD63/Y235A and WT CD9 were enriched at 
the plasma membrane whereas WT CD63 and CD9/YEVM were targeted to endosomes (Fig. 4A-
D). Furthermore, we observed that redirecting CD63 from endosomes to the plasma membrane of 
NIH3T3 cells led to a significant increase in its relative budding from the cell (5.7 +/- 0.7 fold, p 
= 0.00058, n = 7; Fig. 4E), similar to what we observed for HEK293 cells. The same was true for 
the CD9 experiments, as and redirecting CD9 from the plasma membrane to endosomes of 
NIH3T3 cells once again led to a significant decrease in its relative budding from the cell (3.3 +/- 
0.6 fold, p = 0.0056, n = 8; Fig. 4F). Thus, NIH3T3 resemble HEK293 cells in their preferential 






Testing the ‘endosome-only’ hypothesis  
A wide array of reviews and research articles assert that exosomes arise solely by budding into 
endosomes, followed by endosome-plasma membrane fusion(Colombo et al., 2014; Crenshaw et 
al., 2018; Desrochers et al., 2016; Mathieu et al., 2019; Thery et al., 2018; van Niel et al., 2018). 
We find this perplexing, in part because there is no compelling body of evidence that exosomes 
cannot bud from the plasma membrane, and in part because no study has even attempted to test 
this prevailing, ‘endosome-only’ hypothesis. Here we subjected this hypothesis to experimental 
interrogation, primarily by testing its core tenet that exosomal cargoes must be targeted to 
endosomes before they can be secreted in exosomes. 
 
The foundation of the ‘endosome-only’ hypothesis is belied by the fact that CD9 and CD81, which 
display the highest relative budding of any exosomal cargo proteins yet reported, are localized 
primarily at the plasma membrane, whereas endosome-targeted CD63 buds 5-15-fold less 
efficiently that either CD9 or CD81. After all, if exosomes only bud via endosomal budding, then 
cargoes that are enriched at endosomes should bud more efficiently than plasma membrane-
localized cargoes. This tenet is also contradicted by the consequences of redirecting CD63 to the 
plasma membrane. Under the prevailing paradigm, this change in subcellular distribution should 
reduce or eliminate the exosomal secretion of CD63, while in reality it led to a ~6-fold increase in 
its exosomal secretion. The prevailing paradigm was similarly unable to predict or explain the 
consequence of redirecting CD9 from the plasma membrane to endosome membranes, which 
resulted in an ~5-reduction in CD9’s exosomal secretion. In fact, every observation in this paper 
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runs counter to the assertion that exosomes are generate exclusively by budding from the 
endosome membrane. Given its consistent inability to predict the outcome of simple empirical 
tests, one cannot help but wonder whether the prevailing paradigm is based on anything more than 
a circular argument in which exosomes are believed to arise by endosomal budding for the sole 
reason that exosomes have been defined in that manner.  
 
Exosomes arise from plasma and endosome membranes 
The simplest interpretation of our data is that cells possess a shared mechanism of exosome 
biogenesis that operates at plasma and endosome membranes, and that HEK293 and NIH3T3 cells 
make most of their exosomes at the plasma membrane. This hypothesis predicts or explains all 
major observations in this report, including:  
(i) the steady-state enrichment of exosome cargoes at both plasma and endosome 
membranes;  
(ii) the ~5-15-fold higher relative budding of CD9 and CD81 relative to CD63;  
(iii) the exosomal secretion of CD63/Y235A;  
(iv) the ~6-fold higher exosomal secretion of CD63/Y235A compared to WT CD63;  
(v) the ~5-fold lower exosomal secretion of CD9/YEVM compared to WT CD9;  
(vi) the exosomal co-localization of CD9 and CD63 on WT CD63 exosomes;  
(vii) the ~4-fold increase in exosomal co-localization of CD9 and CD63 on CD63/Y235A 
exosomes compared to WT CD63 exosomes; 
(viii) the ~4-fold decrease in exosomal co-localization of CD81 on CD9/YEVM exosomes 
compared to WT CD9 exosomes; and  
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(ix) the ~1.7-fold increase in CD63 on CD9/YEVM exosomes compared to WT CD9 
exosomes.   
 
The model of exosome biogenesis posited here is also consistent with prior observations of 
exosome biogenesis via the plasma membrane(Anderson, 1969; Anderson et al., 2005; Bianchi et 
al., 2014; Booth et al., 2006; Cantaluppi et al., 2012; Casado et al., 2017; Fang et al., 2007; Shen 
et al., 2011a; Shen et al., 2011b) as well as prior observations of exosome biogenesis via endosome 
membranes(Colombo et al., 2014; Crenshaw et al., 2018; Desrochers et al., 2016; Harding et al., 
1983; Harding et al., 1984; Mathew et al., 1995; Mathieu et al., 2019; Pan and Johnstone, 1983; 
Pegtel and Gould, 2019; van Niel et al., 2018). Furthermore, it adheres to the principle of maximum 
parsimony by offering a simpler explanation for a wider array of data than is possible under the 
‘endosome-only’ hypothesis of exosome biogenesis. 
 
Implications for exosome composition and heterogeneity 
Although our data indicate that a single mechanism of exosome biogenesis operates across the 
spectrum of endosome and plasma membranes, this model does not predict a uniform composition 
of secreted exosomes. To the contrary, it predicts that the composition of each individual exosome 
will be determined primarily by the local, nanometer-scale concentrations of exosome cargoes in 
the immediate vicinity of each nascent exosome, which are then fixed by its scission from its parent 
membrane.  This prediction is supported by several of our observations, including the increased 
exosomal co-localization of CD9 on CD63/Y235A exosomes, the decreased exosomal co-
localization of CD81 on CD9/YEVM exosomes, and the increased exosomal co-localization of 
CD63 on CD9/YEVM exosomes.  
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This model also provides a simple yet elegant explanation for the pronounced compositional 
heterogeneity of exosomes as the vesicular manifestation of nanometer-scale heterogeneities in the 
plasma and endosome membranes that give rise to exosomes. Compositional heterogeneity of 
these membranes is an established fact(Bernardino de la Serna et al., 2016; Sevcsik et al., 2015; 
Sevcsik and Schutz, 2016; Specht et al., 2017), and these heterogeneities are generated by both 
mechanistic and stochastic forces. For example, the protein sorting machineries that distribute 
cargoes along the spectrum of endosome and plasma membranes display significant-to-subtle 
differences in affinity for virtually every protein with which they interact(Traub and Bonifacino, 
2013), resulting a spectrum of large-scale distribution patterns of these proteins along the spectrum 
of plasma and endosome membranes. In addition, each cargo molecule will experience a range of 
stochastic forces further affecting their nanometer-scale concentration at these membranes, 
including diffusion, structural fluctuations, and various intermolecular interactions. The 
combination of these forces, together with the varied size of exosomes, indicates that each 
exosome cargo molecule will emerge at various levels on exosomes of varied size, with few if any 
having the exact same size and amount of any one protein. This prediction corresponds rather well 
with our SPIRI-IFM data, in which we interrogated thousands of HEK293-derived exosomes for 
just two parameters, size and CD9 abundance, and found that each exosome had a nearly unique 
combination of size and CD9 staining. If one assumes that a similar heterogeneity is seen for the 
thousands of proteins, nucleic acids, and lipids that are incorporated into exosomes by a single cell 
line(Li et al., 2016), it may be that no two exosomes are alike. 
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It should be noted that this model predicts additional contributors to structural and functional 
heterogeneity.  For example, exosomes that arise by budding from the plasma membrane are likely 
influenced by the high complexity of the extracellular milieu, whereas those that bud into 
endosomes are affected by its low pH and abundance of hydrolytic products (e.g. peptides, lipids, 
etc.). Exosomes may also arise by budding into intracellular plasma membrane-connected 
compartments (IPMCs), and this environment may also affect exosome composition and 
function(Nkwe et al., 2016; Pelchen-Matthews et al., 2012). IPMCs are virtually indistinguishable 
from multivesicular bodies (MVBs) but are not endosomes at all, as their lumens are contiguous 
with the extracellular space and their membranes are continuous with the cell surface. These 
different sites of origin can also impart a temporal heterogeneity in exosome release, as vesicles 
retained within MVBs or IPMCs can be released in a delayed and pulsatile manner via endosome 
fusion with the plasma membrane(Sung et al., 2015; Verweij et al., 2018) and IPMC 
opening(Pelchen-Matthews et al., 2012), respectively. 
 
 
Applications to exosome engineering 
The mechanisms of exosome biogenesis have important implications for the more prosaic topic of 
exosome engineering. Exosomes are being developed as therapeutics and drug-delivery vehicles 
for a number of applications(Gilligan and Dwyer, 2017; Kamerkar et al., 2017; Li et al., 2017), 
some of which involve genetic engineering of exosome-producing cells(Yim et al., 2016). Efficient 
exosome engineering requires a solid understanding of exosome biogenesis, as the pathway of 
exosome biogenesis is the blueprint for exosome design. From this perspective, the ‘endosome-
only’ hypothesis of exosome biogenesis does not appear to be particularly helpful, as it wrongly 
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predicts that putative new exosome cargoes should be sent to the endosome membrane.  In contrast, 
the hypothesis posited here provides a validated roadmap for the first two steps in exosome 
engineering. Specifically, it suggests that exosome engineers (i) test whether the exosome 
producing cell line of choice makes exosomes predominantly from plasma or endosome 
membranes, and then (ii) engineers the putative new exosomal cargo so that cells direct it too that 
location. However, additional steps are also likely involved, in part because most plasma 
membrane proteins are not targeted to exosomes(Escola et al., 1998; Thery et al., 1999) and in part 
because protein targeting to exosomes is induced by high-order oligomerization of plasma 




It is also useful to consider whether a two-mechanism model could explain the biogenesis of 
exosomes. For example, is it possible that cells possess one pathway that mediates the exosomal 
secretion of ‘class A’ cargoes, such as CD9 and CD81, and a second, separate pathway that 
mediates the budding of ‘class B’ cargoes, such as CD63? To answer this question it is first 
necessary to accept that the word separate means distinct and non-overlapping. This is obvious 
from its dictionary definition, but also from the cell biological principle of protein 
topogenesis(Blobel, 1980; Blobel, 1995), in which separate organelles are defined in large part by 
their mechanistic connection to separate protein sorting pathways. This means that two-pathway 
models of exosome biogenesis demands that the exosomal co-localization of Class A and Class B 
cargoes is either minimal or absent.  
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The data in our paper argue strongly against a two-pathway model of exosome biogenesis, for the 
simple reason that we detected significant exosomal co-localization of Class A and Class B cargoes 
in every exosome sample we examined. For example, exosomal co-localization of CD9 and CD63 
was observed on a relatively low but nonetheless highly significant percentage of exosomes, as 
~25% of WT CD63 exosomes contained both of these Class A and Class B cargoes. Furthermore, 
their exosomal co-localization could be increased further, rising to ~90% merely by redirecting 
CD63 to the plasma membrane. Significant exosomal co-localization of Class A and B cargoes 
was also evident on a significant percentage (~20%) of WT CD9 exosomes, which was doubled 
to ~40% by redirecting CD9 to endosomes.  
 
Another possible permutation of the two-pathway model would be to restate the Class A pathway 
as mediates the budding of proteins from the plasma membrane while a Class B pathway mediates 
protein budding from endosomes. This version of the two-pathway model posits that misdirecting 
plasma membrane cargoes to the endosome should inhibit its exosomal secretion, which actually 
matches the data we obtained by redirecting CD9 to endosomes (a 5-fold reduction in CD9 
budding). However, this hypothesis also predicts that CD63 budding should also decrease upon its 
redistribution to the plasma membrane, which runs counter to the fact that it induced a ~6-fold 
increase in its exosomal secretion. It also predicts a dearth of exosomal co-localization of CD9 and 
CD63, and is similarly undermined by the contradictory observations outlined in the preceding 
paragraph. 
 
In light of these considerations it seems that the only way to square our data with a two-mechanism 
model of exosome biogenesis would be to: (i) reject the conventional meaning of the word 
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‘separate’ and redefine it to mean ‘pretty much the same’; (ii) ignore the well-established principles 
of protein topogenesis, in which organelle identity is driven by non-overlapping protein sorting 
pathways(Blobel, 1980; Blobel, 1995); and (iii) posit that cells somehow evolved two separate 
pathways of exosome biogenesis that accept the same sets of cargo proteins, secrete them from the 
cell in exosomes of the same size and molecular characteristics, and have no discernable 
difference. It seems far more logical to adhere to the principle of maximum parsimony and go with 
the far simpler model, in which cells use a shared pathway for exosome biogenesis from plasma 
and endosome membranes. 
Acknowledgments 
We thank Colin Fowler, James Morrell, and Jerry Plange of the Gould lab and Aditya Dhande of 





F.K.F. performed all experiments other than the coupled SPIRI-IFM analyses, contributed to the 
experimental design, data interpretation and writing of the paper; G.G.D. performed all SPIRI-
IFM analyses and contributed to the experimental design, data interpretation and writing of the 
paper; S.J.G. conceived of the project, contributed to the experimental design, data interpretation, 
performed the majority of the SPIRI-IFM analysis, and composition of the manuscript. 
 
 
Competing interests  
 60 
F.K.F. receives royalties from the commercial use of mutant HEK293 cell lines and altered 
exosomes described in this paper.  
G.G.D. is co-founder, CSO, co-owner, and employee of Nanoview Biosciences, which produces 
and sells the Exoview imaging system and related materials.  
S.J.G. receives royalties from the commercial use of mutant HEK293 cell lines and altered 
exosomes described in this paper. 
 
 
Materials & Correspondence 
Correspondence and material requests should be addressed to: 
Dr. Stephen Gould 
Professor of Biological Chemistry 
Johns Hopkins University 





Tel: (01) 443 847 9918 
 
 61 
Methods   
 
Plasmids 
The CD9 knock-out plasmid pJM1084 was generated by inserting CD9 gene-specific guide RNA-
encoding sequences specific for CD9 exons 1 and 3, respectively, were inserted  downstream of 
the 7sk and H1 promoters, respectively, of pFF4(Fordjour et al., 2016). Plasmids pCF1, pCF2, 
pCF6, and pCF7 were created by inserting the ORFs encoding CD63, CD63/Y235A, CD9, and 
CD9/YEVM downstream of the CMV promoter of pcDNA3. Plasmids were amplified by growth 
in E. coli DH10 and purified by ion exchange chromatography from bacterial cell lysates. 
 
Cells, transfections 
HEK293 cells (ATCC CRL1573), HEK293 CD63-/- cells(Fordjour et al., 2016), HEK293 CD9-/- 
cells and NIH3T3 cells (ATCC CRL-1658) were grown in DMEM supplemented with 10% fetal 
calf serum (FCS) or 10% exosome-free FCS, with all exosome-related studies performed using 
cells grown in the latter. HEK293 cells carrying null mutations in CD9 (CD9-/-) were generated by 
transfecting HEK293 cells with pJM1084, selecting for puromycin-resistant cells (7 days), 
followed by limiting cell dilution into  96 well plates and expansion of single cell clones (SCCs). 
Multiple independent SCCs were screened by IB using anti-CD9 antibodies, followed by genomic 
DNA extraction, PCR analysis using oligos that flank both sides to the exon 1 and exon 3 target 
sites, and sequence analysis of individual PCR products. The CD9-/- cell line selected for further 
analysis here was found to carry only null alleles in the CD9 gene. Transfections were performed 
using lipofectamine 2000 (ThermoFisher) according to the manufacturer’s instruction. NIH3T3 
cells expressing WT CD63, CD63/Y235A, WT CD9 or CD9/YEVM were selected in 400 g/ml 
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G418 (ThermoFisher), clones expressing similar level of each pair protein were identified, and 
then used for subsequent experiments. 
 
Exosome purification and immunoblot 
For each trial, 6 x 106 cells were seeded onto 2 x 150 mm dishes in a total volume of 60 ml of 
DMEM supplemented with 10% exosome-free FCS and grown for 72 hrs. For all exosome studies, 
the tissue culture media was spun at 5000 x g for 15 min. The pellet was discarded and the 
supernatants (SN) were passed through 0.22 um filter. For exosome analysis by SPIRI and IFM, 
the filtrate was concentrated by angular flow filtration (Centricon Plus-70; EMDMillipore) to a 
final volume of to 500ul. Exosomes were purified by size exclusion chromatography (Izon qEV 
column), 500ul fraction samples were collected, and fractions 4, 5, and 6 were assayed by 
immunoblot (IB) to confirm the presence of exosome markers, pooled, and interrogated by SPIRI 
and IFM. For exosome analysis by IB, the clarified tissue culture supernatant was spun twice at 
10,000 x g for 30 mins to remove contaminating microvesicles, and the resulting supernatant was 
spun at 70,000 x g for 2 hrs at 4oC to pellet exosomes. Cell lysates were generated by addition of 
2 ml of 2x SDS-PAGE sample buffer. Exosome pellets were resuspended in 600ul of 2x SDS-
PAGE sample buffer.  Immunoblots were performed at a constant ratio of exosome:cell lysates. 
IB analysis was performed by separating cell and exosome lysates by SDS-PAGE. Proteins were 
then transferred to Immobilon membranes (EMDMillipore), followed in sequence by incubation 
with block solution (0.2% non-fat dry milk in TBST), primary antibody solution, 5 washes with 
TBST, secondary antibody solution, and 5 washes with TBST. Antigens were visualized by 
chemiluminescence and detected using an Amersham Imager 600 (GE Healthcare Life Sciences) 
gel imaging system. The resulting digitized IB images were then processed in Image J by 
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converting them to 8-bit grayscale files followed by background subtraction. Measurement 
parameter and scale were set to integrated density and pixel, respectively. Images were then 
inverted, bands were delineated using the freehand selection tool, and signal densities were 
converted to relative protein abundance by multiplying by the dilution factor for each sample. 
Relative budding was calculated by dividing the protein abundance in exosome lysate by the sum 
of the protein abundance in the cell lysate and the protein abundance in exosome lysate. 
 
Immunofluorescence microscopy 
Immunofluorescence microscopy (IFM) was performed on cells grown on cover glasses. Cells 
were fixed (3.7% formaldehyde in PBS for 15 min.), permeabilized (1% Triton X-100 in PBS for 
5 min.), incubated with primary antibodies in PBS (15 min.), washed 3 times with PBS, incubated 
with fluorescently-labeled secondary antibody and DAPI, washed 3 times with PBS, mounted on 
glass slides, and visualized by confocal microscopy. Antibodies were diluted in PBS (1:200 
dilution for CD63 (clone E-12, #sc-365604, Santa Cruz Biotechnology), 1:200 dilution for CD9 
(clone H19a, #312102, Biolegend), 1:1000 dilution of fluorescein (FITC) AffiniPure Goat Anti-
Mouse IgG (H+L) (#115-095-003 Jackson Laboratory). Confocal images were acquired using a 
Zeiss AxioObserver inverted microscope with LSM700 confocal module and 63x, 1.4 aperture 
AxioPlan objective. Images were acquired using Zen software, converted to tiff files, and imported 
into Adobe Photoshop and Illustrator to create final images. Standard immunofluorescence 
imaging of NIH3T3 cells was performed at room temperature on a BH2-RFCA microscope 
(Olympus) equipped with an Olympus S-plan Apo 63× 0.40 oil objective and a Sensicam QE 
(Cooke) digital camera using IPLab 3.6.3 software (Scanalytics, Inc.). Again, tiff images were 
imported into Adobe Photoshop and Illustrator to create final images. 
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SPIRI and IFM analysis 
Each exosome sample was diluted ten-fold in SPIRI incubation buffer (50mM HEPES, 150 mM 
NaCl and 0.05% Tween-20, pH 7.3). 35 µL of each sample were then incubated on the ExoView 
Tetraspanin Chip (EV-TC-TTS-01) placed in a sealed 24 well plate for 16 hours at room 
temperature. Each chip was then washed on an orbital shaker once with PBST (PBS supplemented 
with 0.05% Tween-20) for 3 minutes, then washed three additional times with PBS for 3 minutes 
each Chips were then incubated with one or more of Alexa-55-labeled anti-CD81, Alexa-488-
labeled anti-CD63, and Alexa-647anti-CD9 antibodies in PBST supplemented with 2% BSA in a 
volume of 250 µL for 2 hours at room temperature without shaking. Each chip was then washed 
once with PBST, 3 times with PBS, once in filtered deionized water, and then dried at room 
temperature for 1 hour. The chips were then imaged with the ExoView R100 reader using the 
ExoScan 2.5.5 acquisition software (Nanoview Biosciences). The resulting size and fluorescence 
intensity information for each individual exosome was exported to Excel for statistical analyses. 
Fluorescence values are reported in arbitrary units. 
 
Data analysis and presentation 
All quantitative data is reported as average +/- standard error of the mean. The statistical 
significance of differences between different data sets was assessed using Student’s t-test (two-
tailed, paired). Histograms and scatter plots were generated using Excel. Images were imported 
into Adobe photoshop and figures were assembled in Adobe Illustrator. Image data was adjusted 




Figure 1. Plasma membrane-localized exosome cargoes CD9 and CD81 display higher relative 
budding than endosome-localized CD63. (A) HEK293 cells were fixed, permeabilized, and stained 
with antibodies specific for CD63, CD9, or CD81, as well as with DAPI (blue), and then imaged 
by confocal microscopy. bar, 10 um. (B) Immunoblot analysis of HEK293 exosome and cell 
lysates reveals that the relative budding of CD63 is 5-fold less than that of CD9 and 16-fold less 
than that of CD81. The bar graph shows the average +/- s.e.m. (n = 4) of the relative budding of 











Figure 2. Redirecting CD63 to the plasma membrane enhances its exosomal secretion and its 
exosomal co-localization with the plasma membrane-enriched exosome marker, CD9. (A) 
Confocal microscopy of HEK293 CD63-/- cells transfected with plasmids expressing either (upper 
panel) WT CD63 or (lower panel) CD63/Y235A, stained with (green) antibodies specific for CD63 
and (blue) DAPI. bar, 10 um. (B) Immunoblot analysis of exosome and cell lysates from HEK293 
CD63-/- cells expressing either CD63 or CD63/Y235A. Bar graph shows average relative budding 
+/- s.e.m. (n = 9) of WT CD63 and CD63/Y235A compared to wildtype CD63; p-value < 0.005. 
(C) Coupled SPIRI and IFM reveal that (upper graph) WT CD63 exosomes and (lower graph) 
CD63/Y235A exosomes have similar size distribution profiles. (D) Bar graphs showing the 
percentages (average +/- s.e.m.) of (upper graph) CD9-captured exosomes that stain positive for 
CD63 and (lower graph) CD63-captured exosomes that stain positive for CD9. Statistical 
significance is denoted by one asterisk (p <0.05), two asterisks (p <0.005) or three asterisks (p 
<0.005). (E) Scatter analysis plotting CD9 fluorescence (a.u.) vs. exosome size on exosomes 
captured on anti-CD63 antibodies for (left plot) WT CD63 exosomes and (right plot) CD63/Y235A 
exosomes. Solid black line denotes the threshold of background fluorescence, as determined by 
staining samples with non-immune IgG. Black line denotes fluorescence background level of 100. 
(F) Scatter analysis plotting CD63 fluorescence (a.u.) vs. exosome size on exosomes captured on 
anti-CD9 antibodies for (left plot) WT CD63 exosomes and (right plot) CD63/Y235A exosomes. 











Figure 3. Redirecting CD9 to endosomes inhibits its exosomal secretion, reduces its exosomal co-
localization with CD81, and increases its exosomal co-localization with CD63. (A) Confocal 
microscopy of HEK293 CD9-/- cells transfected with plasmids expressing either (upper panel) 
wildtype CD9 or (right panel) CD9/YEVM, stained with (green) antibodies specific for CD9 and 
(blue) DAPI. bar, 10 um. (B) Immunoblot analysis of cell and exosome fractions from HEK293 
CD9-/- cells expressing either CD9 or CD9/YEVM. Graph shows average relative budding +/- 
s.e.m. (n = 9) of CD9 compared to CD9/YEVM; p-value <0.0005. (C) Size distribution of (upper 
graph) CD9-containing exosomes (upper graph) and (lower graph) CD9/YEVM-containing 
exosomes, as determined by coupled SPIRI and IFM. (D) Bar graphs showing (upper graph) the 
ratio of CD81-positive exosomes to CD63-positive exosomes captured by anti-CD9 antibodies 
from CD9 exosomes and CD9/YEVM exosomes; (middle graph) the percentage of CD81-positive 
exosomes captured on anti-CD9 antibodies from CD9 exosomes and CD9/YEVM exosomes; and 
(lower graph) the percentage of CD9-positive exosomes captured on anti-CD63 antibodies from 
CD9 exosomes and CD9/YEVM exosomes. Each value represents that average +/- s.e.m., and the 
degree of statistical significance is denoted by one asterisk (p <0.05), two asterisks (p <0.005) or 
four asterisks (p <0.0005). (E) Scatter analysis of CD81 fluorescence intensity (a.u.) plotted 
against exosome diameter, of exosomes captured on anti-CD9 antibodies from (left plot) WT CD9 
exosomes and (right plot) CD9/YEVM exosomes. Black line denotes fluorescence background 
level of 300. (F) Scatter analysis of CD9 fluorescence intensity (a.u.) plotted against exosome 
diameter, of exosomes captured on anti-CD63 antibodies from (left plot) WT CD9 exosomes and 
(right plot) CD9/YEVM exosomes. Black line denotes fluorescence background level of 250. 
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Figure 4: NIH3T3 cells bud exosome cargoes preferentially from plasma membranes. (A-D) IFM 
of NIH3T3 cells stably expressing (A) WT human CD63, (B) human CD63/Y235A, (C) WT 
human CD9, or (D) human CD9/YEVM. Cells were fixed, permeabilized, incubated with 
monoclonal antibodies specific for (A,B) human CD63 or (C,D) human CD9, stained with 
secondary antibodies specific for mouse IgG and also with DAPI to detect the nucleus. Bar, 10 
um. (E) Immunoblot analysis of cell and exosome fractions collected from NIH3T3 cells stably 
expressing WT CD63 or CD63/Y235A, followed by calculation of relative budding and 
appropriate statistical analysis. (F) Immunoblot analysis of cell and exosome fractions collected 
from NIH3T3 cells stably expressing WT CD9 or CD9/YEVM, followed by calculation of relative 






Supplementary Figure 1: CD9-/- HEK293 cells do not express CD9 protein. Immunoblot analysis 
of WT HEK293 cells and HEK293 CD9-/- cells using antibodies specific for CD98, CD63, CD81, 
and actin shows that CD9-/- cells do not produce CD9 protein but exhibit no apparent change in 
the expression of CD63, CD81, or actin.   
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Chapter 3: Trans-acting factors involved in exosome biogenesis 
 
Sections of this chapter are derived from: 
Francis K Fordjour, Shawn Owiredu, Hayley Muendlein, Jerry Plange, James Morrell, Jingnan 
Han, Stephen J Gould. Creation of CD63-deficient HEK293 cell lines using a polycistronic 
















Genetic analysis of a cell biological process presumes that the process occurs at a relatively 
constant steady state in the parental cell line, as it allows one to associate changes in the process 
(or lack thereof) to the loss of one or more specific genes and gene functions. Using HEK293 cells 
as our ‘parental’ human cell line, we used Cas9/sgRNA-based mutagenesis technology to generate 
null mutants in genes encoding (a) common exosomal protein cargoes (e.g. CD9, CD63, CD81, 
etc.) and (b) proteins thought to be involved in exosome biogenesis (e.g. Alix, syntenin). Our 
results demonstrate that cell lines lacking these (and other factors) showed no significant decrease 
in exosome concentration and the vesicular budding of known exosomal cargo proteins. However, 
we also observed significant clone-to-clone variability in the relative budding of several exosomal 
cargo proteins. Given that the high frequency with which we observed this ‘enhanced exosome 
production’ phenotype was inconsistent with its being caused by either the introduced mutations, 
or of Cas9-induced second-site mutations, we tested whether the parental HEK293 cell line 
contained cells that varied significantly in exosome biogenesis. It did, as different single-cell 
clones (SCCs) derived from unmutated HEK293 cells varied up to 5-fold in exosome biogenesis. 
These high-producing (HP) and low-producing (LP) phenotypes were semi-stable over period of 
up to 2 months in culture. However, when we generated a new round of SCCs from the cloned HP 
and LP derivatives of HEK293 cells, we observed significant variations in exosome production 
between clones. To test whether the secondary clones were stable or whether the heterogeneity 
breeds through, we single cell cloned the secondary clones and noticed significant variations in 
exosome production. We further observed that this phenotype was not peculiar to HEK293 as 
wildtype 293T, K562, LX-2, HAP1 and WA09 hESC showed significant heterogeneity in exosome 
production when single cell cloned. These results indicate that the relative rate of exosome 
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production can vary significantly in the absence of mutagenesis and be inadvertently exposed 
during the isolation of SCCs. The mechanistic basis of this semi-stable phenotype switching 
remains to be determined. 
 
Introduction 
Exosomes are small membrane bound organelles that are released from the plasma and 
endosome membranes of eukaryotic cells(Pegtel and Gould, 2019). These vesicles are enriched 
for proteins, lipids, carbohydrates and nuclei acids and have the same topology as the cell. 
Exosomes have been shown to play important roles in a number of physiological and pathological 
processes but the mechanisms by which they are made are not fully understood. 
Several genes/proteins have been reported to have some sort of influence on EV 
biogenesis(Baietti et al., 2012; Colombo et al., 2013; Ghossoub et al., 2014; Ostrowski et al., 2010; 
Perez-Hernandez et al., 2013; Roucourt et al., 2015; Savina et al., 2002; Trajkovic et al., 2008). 
Most of these studies have not employed cell lines lacking the gene of interest, and the results have 
instead been based on addition of chemical inhibitors, overexpression of dominant negative 
proteins, or gene silencing techniques using transfected siRNAs and/or shRNA expression vectors. 
Another complication of these studies is that they have been performed in a wide array of cell lines 
with no systematic analysis of all genes in a single experimental system.  
In this paper, we improve our mechanistic understanding of exosome biogenesis using the 
CRISPR (Clustered Regulatory Interspaced Short Palindromic Repeats)/Cas9 technology in a 
defined system (HEK293) to generate null mutants of candidate genes that have been implicated 
in exosome biogenesis. We then assessed their effects on the budding of exosomal marker proteins, 
primarily CD63, CD81, and CD9.  
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The CRISPR/Cas9 technology is an RNA-dependent DNA endonucleases system for 
genome editing(Cong et al., 2013; Mali et al., 2013). Typically, a type II CRISPR system functions 
by the CRISPR RNA (crRNA) interacting with a trans-activating crRNA (tracrRNA) to form a 
crRNA:tracrRNA duplex [this RNA duplex could be replaced with a single guide RNA (sgRNA)], 
which directs Streptococcus pyogenes Cas9 (SpyCas9) to specific sites, thereby generating a DNA 
strand break(Jinek et al., 2012). This break is then repaired in an error prone non-homologous end 
joining resulting in an insertion and /or deletion; when a template is introduced to the area of 
breakage, a homology directed repair could be achieved(Aird et al., 2018). 
 
Results & Discussion 
Creating plasmids to target specific genes implicated in exosome biogenesis 
As discussed in Fordjour et al. 2016, we designed a base plasmid for generating Cas9-induced 
mutations. This plasmid expresses (a) two sgRNAs from the PolIII 7sk(Murphy et al., 1986)  and 
H1(Baer et al., 1990) promoters, and (b) a large, polycistronic ORF from the CMV promoter that 
encodes Cas9-3xNLS(Cong et al., 2013), EGFP(Zhang et al., 1996), HSV-TK(McKnight, 1980), 
and Puro(Vara et al., 1985), each separated by the p2a peptide(Kim et al., 2011) to mediate their 
release as separate polypeptides (Fig. 1). The rationale for expressing two sgRNAs/gene is that it 
should (a) induce deletions between the two targeting sites, and (b) allow for mutations at one site 
if the sgRNA targeting the other site is ineffective. To generate mutants in a particular gene, we 
altered the base plasmid by inserting gene-specific sequences that direct the two sgRNAs to two 
different sites in the target gene. For CD9, we designed the sgRNAs targeting exons 1 and 3, and 
exons 2 and 3 for CD81. We targeted exons 1 and 8 in Alix gene, and exons 2 and 3 of syntenin.  
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Generating null mutant cell lines 
We generated cell lines lacking the classical exosomal markers and other putative cargoes using 
the protocol described in Fordjour et al., 2016. Specifically, we transfected HEK293 cells with the 
expressing plasmid, selected in media containing puromycin after 48 hours, and expanded them 
into single cell clones.  We screened single cell clones emerging from this process first by 
immunoblot (IB), to identify SCCs lacking expression of the protein (Figure 2). We then 
determined the mutations at each allele in cell lines by isolating genomic DNA, performing PCR 
using primers specific to the targeted exons, generating multiple subclones from each PCR reaction 
product, and sequencing multiple independent gDNA amplification products. Our mutational 
analysis is shown on Table 1. Consistent with our preselection for SCCs that lack cross-reactive 
material (CRM), we found that most of the targeted alleles contained short indels resulting in non-
sense, frameshift, or splice site mutations that are predicted to inactivate the allele through a 
combination of non-functional ORF, nonsense mediated RNA decay and/or protein 
instability(Kurosaki and Maquat, 2016). 
 
Loss of CD63, CD9 or CD81 does not cause a defect in budding of classical exosomal markers 
To test whether the loss of CD63, CD9 or CD81inhibits the budding of exosomal marker proteins, 
we measured the relative budding of endogenously expressed, highly enriched exosomal cargo 
proteins by immunoblot (IB) analysis. Specifically, we collected cell and exosome fractions from 
each mutant cell lines, used IB to measure the level of each marker in cell and exosome samples, 
and calculated the relative budding of each marker in the knockout cell line by dividing the amount 
in the exosome fraction by the sum of the amount in cell and exosome fractions. Our results 
demonstrate robust budding of these markers in each mutant, and no significant difference from 
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the amount of budding detected in the parental HEK293 cell line (Figure 3). Interestingly, observed 
a variable increase in exosomal marker protein budding in selected knockout clones.  For example, 
in Figure 4, we observed a significantly higher relative budding of CD9 and CD81 in 3 out of 4 
HEKCD63KO mutant clones. Due to the significant differences in budding of classic markers 
between clones of the same mutant cell lines, we do not think the enhanced budding is a result of 
the absence of gene. 
 
Exosome biogenesis is unaffected by the loss of CD63, CD9, or CD81 
To determine whether the loss of CD63, CD81 or CD9 affects the budding of vesicles in HEK293 
cells, we cultured cells in DMEM+10% Exo-free FBS for 3 days and isolated the exosomes by 
ultracentrifugation. We then measured the concentration of exosomes using the Particle Metrix 
ZetaView Nanoparticle Tracking device(Dragovic et al., 2011). This instrument captures the 
Brownian motion of vesicles in a video, and its concentration is calculated from analyzing the 
video frames for observed vesicle numbers and then normalizing to the volume loaded and cell 
count(Gercel-Taylor et al., 2012). We did not observe any significant differences in the 
concentration of vesicles isolated from HEK293 cells lacking CD63, CD81 or CD9 to vesicles 
from wildtype HEK293 (Figure 5). 
 
Budding of exogenous AcylTyA is not affected by the loss of classical exosomal markers 
To investigate whether the loss of CD63, CD9 or CD81 had any effect on the budding of other 
exosomal proteins, we expressed AcylTyANeonGreen (AcylTyAmNG), a synthetic exosomal 
cargo, in parental and mutant cells lacking CD63, CD81 or CD9 by transfecting these cells with 
an expression vector and selecting for transgenic cell lines by addition of antibiotic. IB analysis 
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revealed that the exosomal secretion of AcylTyAmNG was not reduced by loss of CD63, CD9, or 
CD81. In fact, we noticed a higher relative budding of this exosomal marker protein in both 
HEK293CD63KO and HEK293CD81KO mutant cells compared to parental HEK293 cells (Figure 
6).  
 
Unmutated HEK293 cell display significant heterogeneity in budding when single cell clone 
We hypothesized that the random elevations in budding which we observed in some clones of the 
mutant cell lines were as a result of the parental cell line having a heterogenous population of cells. 
To test this hypothesis, we single cell cloned wildtype HEK293 and measured the relative budding 
of CD63 by immunoblot. We observed that the relative budding of CD63 varied from one clone 
to another even in the absence of mutagenesis (Figure 7). To test if a single clone is stable and can 
generate a homogenous population, we sub-cloned one of the high exosome producing cell (HXP) 
(Figure 8a) and one low exosome producing cell (LXP) (Figure 8b). We observed the new clones 
whether from the HXP or LXP had different relative budding. We however noticed that majority 
of the clones from the HXP were still high exosomes producers and a high frequency of the clones 
from the LXP still had low relative budding of CD63. We generated tertiary clones from the one 
of HXP and LXP subclones, and observed the same phenotype (Figure 9a & 9b). We concluded 
that single cell cloning exposes heterogeneity in budding of cargoes even in the absence of 
mutagenesis. To investigate if there were other cell lines which we could get a homogenous 
population of cell for our work, we generated multiple single cell clones (SCCs) of K562 (Figure 
10a), HAP1 (Figure 10b), LX-2 and human embryonic stem cell line WA09 (Figure 11). In each 
case, we identified SCCs that displayed pronounced cone-to-clone heterogeneity in exosome 
biogenesis, indicating that all human cell lines tested display clonal heterogeneity, making a 
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Figure 1: Plasmid map. The two guide RNAs (yellow) are designed to be expressed from the 7sk 
and H1 PolIII promoters marked in red arrow. The CMV promoter (purple) drives expression of 
a single long ORF (yellow/black line) that encodes Cas9-3xNLS (orange), EGFP (bright green), 
HSV-tk (blue) and Puro (olive green) each separated by p2a peptide to mediate their release as 





  Clone Allele Mutational Analysis 
CD81-1  1 
deletion between exon 2 and 3, 139bp deletion in ORF, 
frameshift 
CD81-1  2 1 bp deletion in exon 2, 95 bp deletion in exon 3/intron 3 
CD81-4  1 
deletion between exon 2 and 3, 139 deletion in ORF, 
frameshift 
CD81-4  2 
deletion between exon 2 and 3, 139 deletion in ORF, 
frameshift 
CD81-8 1 1 bp deletion in exon 3 
CD81-8 2 in-frame deletion between exon 2 and 3 
CD9-2 1 
2 nt insertion in exon 1, 4 nt insertion and 27 bp deletion at 
the 5’ end of exon 3 
CD9-2 2 
58 bp deletion at 3’ end of exon 1, 19 bp deletion of 5’ end of 
exon 3 and 109 deletion of exon 2; in-frame  
Alix-1 1 
85 nt insertion from Chr17 at the first cut site resulting in an 
in-frame STOP, and 6 nt deletion at the second cut site 
Alix-1 2 deletion of 824 bp between exons 1 and 8, frameshift 
Alix-4 1 
1 nt deletion at the 3’ of exon 1, frameshift resulting in a 
STOP 
Alix-4 2 deletion of 824 bp between exons 1 and 8, frameshift 
Alix-6 1 
58bp insertion from the transfected plasmid includes STOP 
codon at the first cut site, and 10 nt deletion at the second cut 
site, frameshift 
Alix-6 2 deletion of 824 bp between exons 1 and 8, frameshift 
Syntenin-
6 1 
1 nt deletion in exon 2 and 2 bp insertion in exon 3, frameshift  
Syntenin-
6 2 




deletion between exon 2 and 5’ end of intron 3, insertion of 
736 bp 
Syntenin-
14 2 deletion of 107nt in ORF, frameshift 
Syntenin-
20 1 
deletion between exon 2 and intron 3, insertion of 283bp of 
intron 2 in an anti-sense orientation 
Syntenin-
20 2 
deletion between exon 2 and 5’ end of intron 3, insertion of 
736 bp 
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Table 1: Mutational analysis of each allele of the various mutant clones. Exon-specific PCR was 






Figure 2: Generating null mutant cell lines, Immunoblot analysis of whole-cell protein lysates 
isolated from multiple independently grown and lysed cultures of HEK293 cells and of SCCs (A) 
CD63ko-4, -15, -23 blotted with antibodies specific for CD63 and beta-actin. CD63 has a 
predicted molecular mass of 26 kDa but runs on non-reducing SDS-PAGE gels as a mixture of 
products of ~35–55 kDa due to heterogeneous glycosylation. In contrast, actin migrates at its 
predicted molecular mass of 42 kDa. (B) CD81ko-1, -4, -8 blotted with antibodies specific for 
CD81 and beta-actin. CD81 has a molecular weight of 24kDa. (C) CD9ko-1, and -2 blotted with 
antibodies specific for (upper panels) CD9 and (lower panels) beta-actin. CD9 has a molecular 
weight of 24kDa. (D) Alixko-1, -4, -6 blotted with antibodies specific for Alix and beta-actin. 
Alix has a molecular weight of 96kDa. (E) Synteninko-6, -14, -20 blotted with antibodies 






Figure 3: Relative budding of CD63, CD9 and CD81 in HEK293 and null mutant cell lines, The 
bar graphs show the average +/- s.e.m. of the relative budding of (A) CD63, (B) CD9, and (C) 
CD81 proteins in HEK293 WT, HEK293 CD63-/- (n=23), HEK293 CD81-/- (n=25), HEK293 








Figure 4: Elevated budding is observed in some mutant clones, The bar graphs show the average 
+/- s.e.m. of the relative budding of (A) CD9 and (B) CD81 proteins in HEK293 CD63-/- mutant 






Figure 5: Exosome biogenesis is unaffected by the loss of CD63, CD81 or CD9. The bar graph 
shows the average +/- s.e.m. number of exosomes per cell of HEK293 WT, HEK293 CD63-/-, 






Figure 6: There is no defect in budding of exogenous cargoes. The bar graphs show the average 
+/- s.e.m. of the relative budding of AcylTyAmNG from HEK293 WT, HEK293 CD63-/-, 







Figure 7: The rate of exosome production varies significantly even in the absence of 
mutagenesis. Bar graph showing the relative budding of CD63 (measured as percentage of 









Figure 8: Clonal heterogeneity persists through generations.  (A) Bar graph showing the relative 
budding of CD63 in HEK293 secondary single clones expanded from a primary high exosome 
producing clone 5 (SCC5), (B) Bar graph showing the relative budding of CD63 in HEK293 






Figure 9: Tertiary clones have varying rates of exosome production. (A), Bar graph showing the 
relative budding of CD63 in HEK293 tertiary single clones expanded from secondary high 
exosome producing clone (SCC5-20). (B), Bar graph showing the relative budding of CD63 in 















Figure 10: Clonal heterogeneity in exosome biogenesis is observed in multiple cell lines. Bar 





Figure 11: Exosome production varies from clone to clone in stem cells. Bar graph showing the 
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Exosomes are released by almost all eukaryotes. The compositions of exosomes can vary 
significantly depending on the physiologic state of the cell and in response to hormones, 
infectious agents, diet and physical activities. We observed about 4-times more CD63, 3-times 
more CD81, and 1.7 times more CD9 in exosomes of 293T cells than in HEK 293 exosomes. We 
hypothesized that the increase in exosome production is a result of the transformed phenotype of 
293T cells since they are derived from HEK 293 cells via the expression of SV40 large T 
antigen. As part of our effort to understand why these cells release larger amounts of these 
exosomal proteins, we screened these cells for the expression and vesicular secretion of 
numerous exosome-associated proteins. We observed no difference in the expression of most 
exosome-associated proteins (e.g. HRS, Alix, CD9, TSG101, MFGE8 etc.) but did detect an ~5-
fold increase in the expression of nSMase2, raising the possibility that altered ceramide 
metabolism might underlie the increase in exosomal protein budding of 293T cells. 
To test if ceramide plays a role, we assessed the ceramide levels in both cell lines, and 
found 293T to have significantly higher level of ceramide than HEK293. We also observed 
another lipid metabolite, diglyceride (DAG) levels to be significantly higher in 293T than in 
HEK293. DAG is a second messenger that can activate protein kinase C (PKC) and turn on 
numerous signal transduction pathways(Huang, 1989). We therefore propose that the increase in 
budding of exosomal classic markers in 293T might be due to the increased levels of ceramide, 
but also to the increased levels of DAG, and that both molecules may promote exosome 
biogenesis by a combination of (a) physico-chemical effects on membrane curvature, as both 
lipids are cone-shaped(Jarsch et al., 2016), and (b) activation of protein kinase signaling 
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pathways, as both molecules are agonists of one or more isoforms of the protein kinase C 
family(Huang et al., 1999).   
 
Introduction  
Proteins bud from cells in small single-membrane bound vesicles called exosomes. These 
vesicles bud from endosome and plasma membranes and have the same topology as cells(Pegtel 
and Gould, 2019). Their sizes range from ~30nm to 200nm, and their compositions can vary 
significantly depending on their site of budding, physiologic state of cell, and in response to 
stress and other signals(Gould and Raposo, 2013; Thery et al., 2006). Exosomes have been 
implicated in many physiological processes and diseases. They have been shown to be involved 
in cellular homeostasis(Takahashi et al., 2017), cell polarity(Lakkaraju and Rodriguez-Boulan, 
2008; Shen et al., 2011) and migration(Shen et al., 2011). The mechanisms by which exosomes 
are made remain unclear. Exosomes were initially thought to be dependent on the ESCRT 
machinery because of the similarity of the process to other membrane scission-dependent 
processes such as MVB biogenesis, virus budding, and cytokinesis(Katzmann et al., 2001). 
However, several studies have established that blocking the ESCRT machinery causes little to no 
defect in exosome cargo protein budding(Colombo et al., 2013; Tamai et al., 2010).  
Trajkovic et al. reported that Oli-neu cells still secreted exosomes when the ESCRT 
machinery was silenced. They observed these exosomes to be enriched in ceramide, and that 
exosome release was reduced following inhibition of the nSMase2 enzyme(Trajkovic et al., 
2008). nSMase2 is a member of the neutral sphingomyelinase family that is active in neutral pH 
and catalyzes the hydrolysis of sphingomyelin (SM), releasing ceramide and the 
phosphorylcholine (PC) head group(Castro et al., 2014; Hannun and Obeid, 2011; Shamseddine 
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et al., 2015). A decrease in exosome release has also been reported in response to the inhibition 
or siRNA induced depletion of nSMase2 in many different systems(Verderio et al., 2018), 
including HEK293 cells(Kosaka et al., 2010), T cells(Mittelbrunn et al., 2011), 
hepatocytes(Nojima et al., 2016), astrocytes(Wang et al., 2012), microglial(Asai et al., 2015) and 
macrophages(Xu et al., 2016). Similar results have been observed in vivo in the context of a 
transgenic mouse model of Alzheimer’s diseases (5XFAD mice), in which exosome reduction 
was caused by the administration of nSMase2 inhibitor(Dinkins et al., 2014). In their subsequent 
studies, the nSMase2 KO mice (fro;5XFAD) displayed a phenotype of reduced exosome 
production in the brain, which lead to the amelioration of Alzheimer’s disease pathology and 
improvement of cognition(Dinkins et al., 2016). Furthermore, elevation of ceramide, either by 
blocking the conversion of ceramide to SM using sphingomyelin synthase (SMS) inhibitor in 
5XFAD mice(Dinkins et al., 2014), or by addition of exogenous C6 ceramide directly to multiple 
myeloma cells(Cheng et al., 2018), increased exosome secretion. 
In this chapter, I explore the differences in budding of exosome cargo proteins in 
HEK293 and 293T cells. Specifically, I employed an immunoblot-based screen of proteins that 
have been previously implicated in exosome biogenesis to see if any are expressed at elevated 
levels in 293T cells. I report here that 293T have significantly higher levels of nSMase2 protein 
than HEK293 cells, and that 293T cells have higher levels of both ceramide and DAG, raising 
the possibility that neoplastic transformation, and/or SV40 T antigen expression, induces 
exosome biogenesis, in part, by increasing the levels of nSMase2 protein and its direct and 




Results & Discussions 
We measured the amount of CD63, CD81 and CD9 in exosome and cell lysates of both 
HEK293 and 293T cells by immunoblot. We then calculated the relative budding of each protein 
in these two cell lines. These experiments revealed that 293T buds ~4.2x more CD63, ~3.6x 
more CD81 and ~1.7x more CD9 than HEK293 cells (Figure 1). To ascertain the mechanisms 
involved in 293T secreting more exosomal markers than HEK293, we screened for proteins that 
have been previously implicated in the exosome biogenesis process. We observed no significant 
difference in the expression of Syntenin, MfgE8, HRS, Alix or Agonaute-2 (Figure 2a). 
However, we found that 293T cells express ~5-fold more nSMase2 than do HEK293 cells 
(Figure 2b). nSMase2 catalyzes the breakdown of sphingomyelin to ceramide and has been 
shown to be involved in a number of physiological processes, including apoptosis, immune 
responses and cell-cycle(Castro et al., 2014; Hannun and Obeid, 2011; Ogretmen and Hannun, 
2004; Verderio et al., 2018). In 2008, Trakjovic et al showed the involvement of nSMase2 in 
exosome production in Oli-neu cells(Trajkovic et al., 2008). They observed exosome secretion 
did not depend on the ESCRT machinery as there was no effect on the production of exosomes 
upon the inhibition of ESCRT. They however observed the secretion of exosomes to be 
significantly reduced upon the pharmacologic inhibition of nSMase2 enzymatic activity and 
proposed that the inhibition of this enzyme resulted in a reduction of ceramide level, which may 
directly affect vesicle formation due to its physico-chemical properties(Jarsch et al., 2016).  
Based on this information, we hypothesized that the increase in nSMase2 levels in 293T 
altered the ceramide levels in the cells which then resulted in the increase in budding of 
exosomal markers. To test our hypothesis, we measured the amount of the ceramide in both 
HEK293 and 293T using acidified Bligh and Dyer(Bligh and Dyer, 1959) and quantified by 
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DGK assay(Hokin and Hokin, 1959). We observed that 293T has 2.5-times more ceramide in the 
cells than HEK293 cells (Figure 3a). In addition, we observed a significant, nearly 2-fold 
increase in diacylglycerol (DAG) levels in 293T cell (Figure 3b). This result, which we did not 
initially expect, makes metabolic sense, as elevated levels of ceramide would be expected to lead 
to higher metabolite flux through the enzyme sphingomyelin synthase, which catalyzes the 
reaction of ceramide with phosphatidylcholine, generating sphingomyelin and DAG. These 
results raise the possibility that the effects of elevating ceramide on exosome biogenesis may be 
mediated by a combination of both ceramide and DAG, both of which may increase exosome 
production by physico-chemical mechanisms, and perhaps also by activating one or more 
















Figure 1: 293T makes more exosomes than HEK293. Bar graphs showing the average +/- s.e.m 
relative budding of (A) CD63, (B) CD81 and (C) CD9 in HEK293 and 293T. (n=4) ** denotes a 
p-value less than 0.005. Right panel shows immunoblots of cell and exosome lysates of HEK293 







Figure 2: Both cells have similar levels of exosome factors except for nSmase2 (A) (Left panels) 
Immunoblots of cell lysates of HEK293 and 293T blotted with antibodies specific for syntenin, 









Figure 3: 293T has 2.5-fold more ceramide and 2-fold more DAG than HEK293 cells. (A) Bar 
graph showing ceramide levels in HEK293 and 293T cells, levels are normalized to lipid 
phosphate. (B): Bar graph showing diglyceride levels in HEK293 and 293T cells, levels are 
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